

CITATION REPORT

List of articles citing

Mutational heterogeneity in cancer and the search for new cancer-associated genes

DOI: 10.1038/nature12213
Nature, 2013, 499, 214-218.

Source: <https://exaly.com/paper-pdf/55878617/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2213	Calcium-induced contraction of the rhizoplast of a quadriflagellate green alga. 1978 , 202, 975-7		161
2212	Tendon injuries of the hand in athletes. 2012 , 11, 201-213		1
2211	Computational approaches to identify functional genetic variants in cancer genomes. 2013 , 10, 723-9		129
2210	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013 , 500, 415-21	50.4	5895
2209	Cholesterol metabolism and Rett syndrome pathogenesis. 2013 , 45, 965-7		12
2208	Differences that matter in cancer genomics. 2013 , 31, 892-3		2
2207	Physical chemistry: Combs for molecules. <i>Nature</i> , 2013 , 502, 307-8	50.4	4
2206	Genomics: Comparisons across cancers. <i>Nature</i> , 2013 , 502, 306-7	50.4	8
2205	Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. 2013 , 155, 948-62		478
2204	The somatic genomic landscape of glioblastoma. 2013 , 155, 462-77		2900
2203	Introduction: sifting through the characterization of hematologic malignancies. 2013 , 50, 284-5		
2202	Detectable clonal mosaicism in the human genome. 2013 , 50, 348-59		26
2201	Pan-cancer patterns of somatic copy number alteration. 2013 , 45, 1134-40		1198
2200	Network-based stratification of tumor mutations. 2013 , 10, 1108-15		546
2199	Computational optimisation of targeted DNA sequencing for cancer detection. 2013 , 3, 3309		20
2198	Mutational landscape and significance across 12 major cancer types. <i>Nature</i> , 2013 , 502, 333-339	50.4	2803
2197	Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. 2013 , 27, 2513-30		174

2196	Genomics traces carcinogen fingerprints. 2013 , 5, 197fs31	1
2195	Making connections: using networks to stratify human tumors. 2013 , 10, 1077-8	3
2194	The causes and consequences of genetic heterogeneity in cancer evolution. <i>Nature</i> , 2013 , 501, 338-45	50.4 1473
2193	The Cancer Genome Atlas Pan-Cancer analysis project. 2013 , 45, 1113-20	3933
2192	APOBEC3B mutagenesis in cancer. 2013 , 45, 964-5	75
2191	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. 2013 , 15, R92	248
2190	IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. 2013 , 32, 97	57
2189	Emerging patterns of somatic mutations in cancer. 2013 , 14, 703-18	366
2188	Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. 2013 , 231, 413-23	73
2187	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. 2013 , 45, 1483-6	219
2186	Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. 2013 , 5, 87	33
2185	High-throughput gene expression and mutation profiling: current methods and future perspectives. 2013 , 8, 401-6	11
2184	Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. 2013 , 4, 2873	236
2183	Comprehensive identification of mutational cancer driver genes across 12 tumor types. 2013 , 3, 2650	350
2182	Unraveling the genetic predisposition to differentiated thyroid carcinoma. 2013 , 98, 3974-6	4
2181	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. 2013 , 110, 18250-5	377
2180	Guanine holes are prominent targets for mutation in cancer and inherited disease. 2013 , 9, e1003816	24
2179	Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. 2013 , 110, E3640-9	24

2178	Single cell heterogeneity: why unstable genomes are incompatible with average profiles. 2013 , 12, 3640-9	38
2177	IntOGen-mutations identifies cancer drivers across tumor types. 2013 , 10, 1081-2	374
2176	Research Highlights. 2013 , 31, 893-893	
2175	Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. 2013 , 45, 1121-6	82
2174	Individual karyotypes at the origins of cervical carcinomas. 2013 , 6, 44	15
2173	Lists of cancer mutations awash with false positives. <i>Nature</i> , 2013 ,	504
2172	The application of high-throughput analyses to cancer diagnosis and prognosis. 46-51	
2171	In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction. 2014 , 9, e97787	62
2170	Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens. 2014 , 9, e106862	28
2169	Dynamic epigenetic control of highly conserved noncoding elements. 2014 , 9, e109326	3
2168	Deciphering cancer heterogeneity: the biological space. 2014 , 2, 12	11
2167	Toward a systematic understanding of cancers: a survey of the pan-cancer study. 2014 , 5, 194	19
2166	Mechanisms of base substitution mutagenesis in cancer genomes. 2014 , 5, 108-46	32
2165	Validation of Next Generation Sequencing Cancer Panels for Clinical Somatic Mutation Profiling-- Identification of Source of Variations and Artifacts using FFPE Tissues. 2014 , 01,	2
2164	Temporal separation of replication and transcription during S-phase progression. 2014 , 13, 3241-8	29
2163	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. 2014 , 4, 1140-53	361
2162	Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. 2014 , 26, 562-7	13
2161	Past, current and future approaches to querying MAPK pathway activation: status and clinical implications. 2014 , 11, 745-760	

2160	Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer. 2014 , 60, 2-13	12
2159	A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. 2014 , 15, 473	52
2158	Next-generation sequencing in precision oncology: challenges and opportunities. 2014 , 14, 635-7	18
2157	Genome-driven integrated classification of breast cancer validated in over 7,500 samples. 2014 , 15, 431	130
2156	Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. 2014 , 3, e27817	157
2155	Precise estimates of mutation rate and spectrum in yeast. 2014 , 111, E2310-8	236
2154	SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. 2014 , 15, 443	47
2153	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. 2014 , 111, E5564-73	275
2152	Postzygotic single-nucleotide mosaicisms in whole-genome sequences of clinically unremarkable individuals. 2014 , 24, 1311-27	39
2151	Global optimization of somatic variant identification in cancer genomes with a global community challenge. 2014 , 46, 318-319	36
2150	Eph family co-expression patterns define unique clusters predictive of cancer phenotype. 2014 , 32, 254-64	7
2149	A cancer theory kerfuffle can lead to new lines of research. 2015 , 107,	57
2148	A combinatorial approach for analyzing intra-tumor heterogeneity from high-throughput sequencing data. 2014 , 30, i78-86	78
2147	The soft genome. 2014 , 3, e989798	12
2146	Is vaccine research still relevant for metastatic melanoma?. 2014 , 1, 91-94	4
2145	The protective role of symmetric stem cell division on the accumulation of heritable damage. 2014 , 10, e1003802	24
2144	p53 requires the stress sensor USF1 to direct appropriate cell fate decision. 2014 , 10, e1004309	25
2143	Identification of drivers from cancer genome diversity in hepatocellular carcinoma. 2014 , 15, 11142-60	35

2142	Predicting cancer prognosis using functional genomics data sets. 2014 , 13, 85-8	9
2141	ContrastRank: a new method for ranking putative cancer driver genes and classification of tumor samples. 2014 , 30, i572-8	16
2140	OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action. 2014 , 30, i549-55	36
2139	Naturally occurring cancers in dogs: insights for translational genetics and medicine. 2014 , 55, 16-45	49
2138	The evolution of thymic lymphomas in p53 knockout mice. 2014 , 28, 2613-20	47
2137	Host genome variations and risk of infections during induction treatment for childhood acute lymphoblastic leukaemia. 2014 , 92, 321-30	5
2136	Mutational landscape of intrahepatic cholangiocarcinoma. 2014 , 5, 5696	220
2135	Mutational landscape of aggressive cutaneous squamous cell carcinoma. 2014 , 20, 6582-92	362
2134	Nano-Oncologicals. 2014 ,	4
2133	Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. 2014 , 135, 2362-9	30
2132	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature</i> , 2014 , 515, 558-62	50.4 1751
2131	Integrated genomic characterization of papillary thyroid carcinoma. 2014 , 159, 676-90	1660
2130	Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. <i>Nature</i> , 2014 , 515, 572-6	50.4 772
2129	Low-grade prostate cancer diverges early from high grade and metastatic disease. 2014 , 105, 1079-85	41
2128	Hypermutation in human cancer genomes: footprints and mechanisms. 2014 , 14, 786-800	274
2127	Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. 2014 , 26, 813-825	216
2126	Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?. 2014 , 7, 941-51	113
2125	Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. 2014 , 20, 21-7	120

2124	Genome network medicine: innovation to overcome huge challenges in cancer therapy. 2014 , 6, 201-8	6
2123	Targeting osteosarcoma. 2014 , 111, 18100-1	11
2122	DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes. 2014 , 6, 44	21
2121	Survival regression by data fusion. 2014 , 2, 47-53	3
2120	The cancer genome atlas research network: a sight to behold. 2014 , 25, 362-5	33
2119	A global assessment of cancer genomic alterations in epigenetic mechanisms. 2014 , 7, 29	46
2118	Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. 2014 , 15, 470	9
2117	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. 2014 , 15, 484	95
2116	MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. 2014 , 15, 489	36
2115	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. 2014 , 2, 167	45
2114	Potential for immunotherapy in soft tissue sarcoma. 2014 , 10, 3117-24	21
2113	DriverDB: an exome sequencing database for cancer driver gene identification. 2014 , 42, D1048-54	60
2112	Advances in small bowel neuroendocrine neoplasia. 2014 , 30, 163-7	7
2111	Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. 2014 , 6, 238ra70	277
2110	Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. 2014 , 26, 340-6	17
2109	NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. 2014 , 2014, bau015	47
2108	A phylogenetic model for understanding the effect of gene duplication on cancer progression. 2014 , 42, 2870-8	7
2107	The genomic landscape of pediatric Ewing sarcoma. 2014 , 4, 1326-41	302

2106	Massive gene amplification drives paediatric hepatocellular carcinoma caused by bile salt export pump deficiency. 2014 , 5, 3850	42
2105	Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. 2014 , 5, 3756	66
2104	Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. 2014 , 9, 1228-34	77
2103	EXPANDS: expanding ploidy and allele frequency on nested subpopulations. 2014 , 30, 50-60	93
2102	Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. 2014 , 32, 2935-7	34
2101	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. 2014 , 124, 453-62	249
2100	Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome. 2014 , 20, 6127-40	72
2099	Spatial and temporal cancer evolution: causes and consequences of tumour diversity. 2014 , 14 Suppl 6, s33-7	14
2098	Phosphatases reverse p53-mediated cell cycle checkpoints. 2014 , 111, 7172-3	16
2097	Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. 2014 , 20, 6605-17	63
2096	Therapeutic implications of immunogenic cell death in human cancer. 2014 , 4, 503	19
2095	Molecular precision chemotherapy: overcoming resistance to targeted therapies?. 2014 , 20, 1064-6	9
2094	Genomic and transcriptional alterations in lung adenocarcinoma in relation to smoking history. 2014 , 20, 4912-24	21
2093	Genome-wide reorganization of histone H2AX toward particular fragile sites on cell activation. 2014 , 42, 1016-25	18
2092	Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. 2014 , 42, 12973-83	3
2091	The fall and rise of pharmacology--(re-)defining the discipline?. 2014 , 87, 4-24	23
2090	Genomes in the clinic: the Gustave Roussy Cancer Center experience. 2014 , 24, 99-106	10
2089	Titin mutation in familial restrictive cardiomyopathy. 2014 , 171, 24-30	64

2088	Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. 2014 , 207, 365-72	95
2087	Clonal evolution in hematological malignancies and therapeutic implications. 2014 , 28, 34-43	120
2086	Analysis of TP53 mutation status in human cancer cell lines: a reassessment. 2014 , 35, 756-65	110
2085	Tumor heterogeneity confounds and illuminates: assessing the implications. 2014 , 20, 342-4	82
2084	Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. 2014 , 20, 344-6	51
2083	Evolution of the cancer stem cell model. 2014 , 14, 275-91	1462
2082	Cancer Systems Biology: a peek into the future of patient care?. 2014 , 11, 167-76	120
2081	NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. 2014 , 134, 2630-2638	214
2080	Tissue prognostic biomarkers in primary cutaneous melanoma. 2014 , 464, 265-81	38
2079	Aging genomes: a necessary evil in the logic of life. 2014 , 36, 282-92	19
2078	Silent mutations make some noise. 2014 , 156, 1129-1131	28
2077	Comprehensive molecular characterization of urothelial bladder carcinoma. <i>Nature</i> , 2014 , 507, 315-22	50.4 1963
2076	Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm. 2014 , 35, 643-53	14
2075	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. 2014 , 25, 91-101	657
2074	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014 , 506, 445-50	50.4 434
2073	Identification of genomic alterations in oesophageal squamous cell cancer. <i>Nature</i> , 2014 , 509, 91-5	50.4 688
2072	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. 2014 , 32, 479-84	434
2071	Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. 2014 , 156, 1298-1311	191

2070	A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. 2014 , 13, 1918-28	69
2069	Genomic and molecular characterization of esophageal squamous cell carcinoma. 2014 , 46, 467-73	398
2068	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. 2014 , 11, 282-98	236
2067	Hypermutable DNA chronicles the evolution of human colon cancer. 2014 , 111, E1889-98	25
2066	Clustered and genome-wide transient mutagenesis in human cancers: Hypermutation without permanent mutators or loss of fitness. 2014 , 36, 382-393	39
2065	Complex correlations: replication timing and mutational landscapes during cancer and genome evolution. 2014 , 25, 93-100	55
2064	Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. 2014 , 60, 1972-82	272
2063	Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. 2014 , 46, 613-7	165
2062	Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. 2014 , 24, 1053-63	147
2061	Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. 2014 , 46, 573-82	695
2060	Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. 2014 , 159, 15-22	6
2059	Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. 2014 , 344, 913-7	160
2058	TP53 mutations in human cancer: database reassessment and prospects for the next decade. 2014 , 35, 672-88	191
2057	Competing views on cancer. 2014 , 39, 281-302	35
2056	Mutational patterns in the breast cancer mitochondrial genome, with clinical correlates. 2014 , 35, 1046-54	49
2055	Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. 2014 , 588, 288-97	95
2054	DNA sequencing of cancer: what have we learned?. 2014 , 65, 63-79	37
2053	The role of replicates for error mitigation in next-generation sequencing. 2014 , 15, 56-62	192

2052	Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. 2014 , 53, 38-51	99
2051	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. 2014 , 5, 2997	564
2050	The evolution of the unstable cancer genome. 2014 , 24, 61-7	52
2049	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. 2014 , 46, 161-5	320
2048	Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. 2014 , 123, 2220-8	412
2047	Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , 2014 , 506, 371-5	50.4 541
2046	Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair. 2014 , 32, 71-5	92
2045	Discovery and saturation analysis of cancer genes across 21 tumour types. <i>Nature</i> , 2014 , 505, 495-501	50.4 1990
2044	Somatic mutation as a mechanism of Wnt/ β -catenin pathway activation in CLL. 2014 , 124, 1089-98	56
2043	Onco-proteogenomics: cancer proteomics joins forces with genomics. 2014 , 11, 1107-13	102
2042	Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. 2014 , 46, 1267-73	491
2041	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. 2014 , 46, 1258-63	215
2040	EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. 2014 , 26, 668-681	223
2039	Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. 2014 , 5, 5477	130
2038	8th international conference on oncolytic virus therapeutics. 2014 , 25, 1062-84	2
2037	One hundred years of somatic mutation theory of carcinogenesis: is it time to switch?. 2014 , 36, 118-20	20
2036	The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. 2014 , 26, 722-37	251
2035	Tumors STING adaptive antitumor immunity. 2014 , 41, 679-81	13

2034	Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. 2014 , 4, 1342-53	310
2033	Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. 2014 , 211, 2213-30	68
2032	Immune-based therapies for childhood cancer. 2014 , 11, 693-703	67
2031	Heterogeneous polymerase fidelity and mismatch repair bias genome variation and composition. 2014 , 24, 1751-64	111
2030	Detecting ultralow-frequency mutations by Duplex Sequencing. 2014 , 9, 2586-606	247
2029	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. 2014 , 6, 5	127
2028	Genetic variation in human DNA replication timing. 2014 , 159, 1015-1026	102
2027	Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. 2014 , 111, 15138-43	99
2026	Reconstructing Mutational History in Multiply Sampled Tumors Using Perfect Phylogeny Mixtures. 2014 , 354-367	10
2025	Approaches to integrating germline and tumor genomic data in cancer research. 2014 , 35, 2157-63	9
2024	Somatic mutations, genome mosaicism, cancer and aging. 2014 , 26, 141-9	91
2023	The emerging genomic landscape of endometrial cancer. 2014 , 60, 98-110	74
2022	Notch activation as a driver of osteogenic sarcoma. 2014 , 26, 390-401	93
2021	Translating genomics for precision cancer medicine. 2014 , 15, 395-415	56
2020	Carcinomes sarcomatoïdes pulmonaires. 2014 , 6, 96-99	
2019	Targeting nucleophosmin 1 represents a rational strategy for radiation sensitization. 2014 , 89, 1106-1114	21
2018	Comprehensive molecular characterization of gastric adenocarcinoma. <i>Nature</i> , 2014 , 513, 202-9	50.4 3659
2017	Clonal evolution in breast cancer revealed by single nucleus genome sequencing. <i>Nature</i> , 2014 , 512, 155-60	50.4 730

2016	Personalized medicine in hematology - A landmark from bench to bed. 2014 , 10, 70-7	9
2015	Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. 2014 , 4, 876-8	4
2014	Comprehensive molecular profiling of lung adenocarcinoma. <i>Nature</i> , 2014 , 511, 543-50	50.4 3310
2013	Integrated genomic characterization of adrenocortical carcinoma. 2014 , 46, 607-12	423
2012	Precision therapy for lymphoma--current state and future directions. 2014 , 11, 585-96	55
2011	Bioinformatics Analysis of Pancreas Cancer Genome in High-Throughput Genomic Technologies. 2014 , 93-131	1
2010	The genomic and epigenomic landscapes of AML. 2014 , 51, 259-72	11
2009	Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. 2014 , 46, 699-724	23
2008	Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. 2014 , 7, 32	38
2007	CRISPR-Cas9 knockin mice for genome editing and cancer modeling. 2014 , 159, 440-55	1089
2006	Genome-wide analysis of noncoding regulatory mutations in cancer. 2014 , 46, 1160-5	367
2005	Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. 2014 , 159, 402-14	126
2004	Cancer: evolution within a lifetime. 2014 , 48, 215-36	146
2003	SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. 2014 , 465, 331-8	15
2002	D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. 2014 , 2, 19	57
2001	RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. 2014 , 26, 61-76	66
2000	MTOR mutations in the crosshairs of targeted therapy. 2014 , 4, 513-5	2
1999	Inferring the paths of somatic evolution in cancer. 2014 , 30, 2456-63	19

1998	Toxicogenomics and cancer susceptibility: advances with next-generation sequencing. 2014 , 32, 121-58	30
1997	Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. 2014 , 46, 872-6	258
1996	Expanding the computational toolbox for mining cancer genomes. 2014 , 15, 556-70	146
1995	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. 2014 , 5, 3518	173
1994	Tumor antigen discovery through translation of the cancer genome. 2014 , 58, 292-9	8
1993	Insights from Genetic Models of Melanoma in Fish. 2014 , 2, 85-92	1
1992	Patterns and processes of somatic mutations in nine major cancers. 2014 , 7, 11	47
1991	Viruses and the DNA Damage Response: Activation and Antagonism. 2014 , 1, 605-25	81
1990	Determinants of mutation rate variation in the human germline. 2014 , 15, 47-70	204
1989	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. 2014 , 32, 1020-30	1684
1988	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. 2014 , 4, 546-53	224
1987	Genome sequencing of normal cells reveals developmental lineages and mutational processes. <i>Nature</i> , 2014 , 513, 422-425	50.4 249
1986	Genetic landscape of esophageal squamous cell carcinoma. 2014 , 46, 1097-102	443
1985	Cancer Bioinformatics. 2014 ,	4
1984	DNA replication timing: Coordinating genome stability with genome regulation on the X chromosome and beyond. 2014 , 36, 997-1004	6
1983	Pancreatic cancer genomics. 2014 , 24, 74-81	40
1982	Evolving understanding of the CLL genome. 2014 , 51, 177-87	22
1981	Accumulation of somatic mutations in TP53 in gastric epithelium with <i>Helicobacter pylori</i> infection. 2014 , 147, 407-17.e3	95

1980	Wild type p53 reactivation: from lab bench to clinic. 2014 , 588, 2628-38	52
1979	Stratification and delineation of gastric cancer signaling by in vitro transcription factor activity profiling and integrative genomics. 2014 , 26, 880-94	10
1978	Genetics of follicular lymphoma transformation. 2014 , 6, 130-40	371
1977	Standardized decision support in next generation sequencing reports of somatic cancer variants. 2014 , 8, 859-73	62
1976	Collection, integration and analysis of cancer genomic profiles: from data to insight. 2014 , 24, 92-8	17
1975	The genomic landscape of nasopharyngeal carcinoma. 2014 , 46, 866-71	225
1974	Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. 2014 , 111, 8589-94	40
1973	HLA-binding properties of tumor neoepitopes in humans. 2014 , 2, 522-9	138
1972	Smoking, p53 mutation, and lung cancer. 2014 , 12, 3-13	157
1971	High-definition reconstruction of clonal composition in cancer. 2014 , 7, 1740-1752	135
1970	Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis. 2014 , 53, 803-14	17
1969	APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. 2014 , 7, 1833-41	235
1968	Mutational context and diverse clonal development in early and late bladder cancer. 2014 , 7, 1649-1663	94
1967	Modelling mutational landscapes of human cancers in vitro. 2014 , 4, 4482	68
1966	Differential and limited expression of mutant alleles in multiple myeloma. 2014 , 124, 3110-7	42
1965	Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1. 2015 , 1, 14009	1
1964	[Immuno-Oncology therapeutic principles in lung and renal cell carcinoma]. 2014 , 37 Suppl 4, 10-3	
1963	The potential of genome-wide analyses to improve non-small-cell lung cancer care. 2014 , 3, 383-396	

1962	The role of APOBEC3B in chondrosarcoma. 2014 , 32, 1867-72	8
1961	The biological and clinical challenge of liver cancer heterogeneity. 2014 , 1, 349-353	26
1960	Cancer genomics: new software tools making sequencing more accessible. 2014 , 11, 127-130	
1959	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. 2015 , 10, 985-9	208
1958	Integrated genomics approach to identify biologically relevant alterations in fewer samples. 2015 , 16, 936	7
1957	The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. 2015 , 136, 844-53	59
1956	Melanocyte UV resistance: Feelin' the endothelin. 2015 , 24, 414-5	1
1955	Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. 2015 , 5, 12566	68
1954	Modeling cancer metabolism on a genome scale. 2015 , 11, 817	122
1953	The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. 2015 , 125, 600-5	14
1952	GI Surgery Annual. 2015 ,	
1951	Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. 2015 , 100, 7-16	39
1950	Analyzing Combinations of Somatic Mutations in Cancer Genomes. 337-361	
1949	Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms. 2015 , e52879	1
1948	Cancer Bioinformatic Methods to Infer Meaningful Data From Small-Size Cohorts. 2015 , 14, 131-9	1
1947	Targeting Breast Cancer Metastasis. 2015 , 9, 23-34	87
1946	Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. 2015 , 7, 608-27	29
1945	Treatment options expanding for advanced melanoma. 2015 , 13, 673-5	1

1944	APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, Gene-Dense, and Active Chromatin Regions. 2015 , 13, 1103-1109	57
1943	Computational methods and resources for the interpretation of genomic variants in cancer. 2015 , 16 Suppl 8, S7	11
1942	Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. 2015 , 7, 87	100
1941	Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. 2015 , 7, 98	64
1940	A critical analysis of cancer biobank practices in relation to biospecimen quality. 2015 , 7, 369-378	10
1939	Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. 2015 , 54, 606-15	84
1938	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. 2015 , 237, 363-78	72
1937	From personalized to patient-specific treatment of metastatic melanoma. 2015 , 2, 193-197	
1936	Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes. 2015 , 16 Suppl 7, S7	21
1935	Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. 2015 , 15, 773	29
1934	Determining the origin of synchronous multifocal bladder cancer by exome sequencing. 2015 , 15, 871	12
1933	TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. 2015 , 8, 58	29
1932	CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. 2015 , 16, 160	132
1931	De novo ChIP-seq analysis. 2015 , 16, 205	7
1930	Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia. 2015 , 7, 28	15
1929	Ancient hot and cold genes and chemotherapy resistance emergence. 2015 , 112, 10467-72	31
1928	Systemic therapy of metastatic melanoma. 2015 , 13, 1223-35; quiz 1236-7	6
1927	Systemtherapie des metastasierten malignen Melanoms. 2015 , 13, 1223-1238	6

1926	Detection of novel germline mutations for breast cancer in non-BRCA1/2 families. 2015 , 282, 3424-37	31
1925	Epigenetic dysregulation of KCa 3.1 channels induces poor prognosis in lung cancer. 2015 , 137, 1306-17	49
1924	Fuzzy Cluster Analysis. 2015 , 1-18	
1923	Immunonkologisches Therapieprinzip beim Lungen- und Nierenzellkarzinom. 2015 , 3, 91-92	
1922	Age-related somatic mutations in the cancer genome. 2015 , 6, 24627-35	68
1921	Epigenetic Reduction of DNA Repair in Progression to Cancer. 2015 ,	
1920	Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer?. 2015 , 1, 15-27	16
1919	Computational characterisation of cancer molecular profiles derived using next generation sequencing. 2015 , 19, A78-91	4
1918	A closer look at papillary thyroid carcinoma. 2015 , 30, 1-6	30
1917	Understanding of Cancer Cell Metabolism and Thyroid Cancer. 2015 , 8, 147	
1916	Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. 2015 , 16, 47-59	34
1915	Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes. 2015 , 16, 16176-215	41
1914	Mining the Dynamic Genome: A Method for Identifying Multiple Disease Signatures Using Quantitative RNA Expression Analysis of a Single Blood Sample. 2015 , 4, 671-89	5
1913	An interpretive review of selective sweep studies in Bos taurus cattle populations: identification of unique and shared selection signals across breeds. 2015 , 6, 167	59
1912	A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. 2015 , 6, 341	5
1911	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. 2015 , 9, 3529-45	101
1910	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. 2015 , 10, e0126762	14
1909	The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. 2015 , 19, A68-77	1337

1908	An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. 2015 , 11, e1004350	21
1907	A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces. 2015 , 11, e1004518	79
1906	A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic Events. 2015 , 11, e1004583	14
1905	Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration. 2015 , 10, e0133503	18
1904	Analysis of Matched Tumor and Normal Profiles Reveals Common Transcriptional and Epigenetic Signals Shared across Cancer Types. 2015 , 10, e0142618	24
1903	Classification of Cancer Primary Sites Using Machine Learning and Somatic Mutations. 2015 , 2015, 491502	15
1902	Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. 2015 , 4, e06907	101
1901	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. 2015 , 30, 48-57	2
1900	The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients. 2015 , 6, 755-70	43
1899	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. 2015 , 6, 17543-58	45
1898	Molecular Abnormalities in Tumors. 2015 , 241-264	
1897	Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy. 2015 , 06,	4
1896	Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. 2015 , 6, 17764-76	104
1895	Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. 2015 , 7, 1959-82	27
1894	An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. 2015 , 7, 203-13	12
1893	Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. 2015 , 5, 7857	54
1892	SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. 2015 , 34, 5699-708	114
1891	On the Sample Complexity of Cancer Pathways Identification. 2015 , 326-337	

1890	Integrative clinical genomics of advanced prostate cancer. 2015 , 161, 1215-1228	1765
1889	Characterization and identification of hidden rare variants in the human genome. 2015 , 16, 340	17
1888	Molecular events in relapsed oral squamous cell carcinoma: Recurrence vs. secondary primary tumor. 2015 , 51, 738-44	22
1887	Simultaneous inference of cancer pathways and tumor progression from cross-sectional mutation data. 2015 , 22, 510-27	18
1886	Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. 2015 , 348, 880-6	983
1885	The cancer cell map initiative: defining the hallmark networks of cancer. 2015 , 58, 690-8	89
1884	CTCF/cohesin-binding sites are frequently mutated in cancer. 2015 , 47, 818-21	286
1883	Recurrent somatic mutations in regulatory regions of human cancer genomes. 2015 , 47, 710-6	190
1882	Oncotator: cancer variant annotation tool. 2015 , 36, E2423-9	332
1881	Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. 2015 , 174, 987-97	19
1880	Vers un dñembrement molñculaire de lñrothñum malin ?. 2015 , 17, 150-157	
1879	Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. 2015 , 42, 201-15, viii	13
1878	SomlnaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering. 2015 , 16, 125	23
1877	Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. 2015 , 33, 1993-4	16
1876	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015 , 521, 489-94	50.4 890
1875	The somatic autosomal mutation matrix in cancer genomes. 2015 , 134, 851-64	14
1874	Gene analysis techniques and susceptibility gene discovery in ñnon-BRCA1/BRCA2 familial breast cancer. 2015 , 24, 100-9	19
1873	Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. 2015 , 6, 6744	666

1872	TP53: an oncogene in disguise. 2015 , 22, 1239-49	170
1871	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. 2015 , 10, 1049-57	72
1870	My, How Things Have Changed in Multiple Endocrine Neoplasia Type 2A!. 2015 , 100, 2532-5	9
1869	From Mutational Mechanisms in Single Cells to Mutational Patterns in Cancer Genomes. 2015 , 80, 117-37	7
1868	Distribution of CD4(+) and CD8(+) T cells in tumor islets and stroma from patients with non-small cell lung cancer in association with COPD and smoking. 2015 , 51, 263-71	12
1867	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. 2015 , 21, 5439-44	76
1866	Allele frequency of somatic mutations in individuals reveals signatures of cancer-related genes. 2015 , 47, 657-60	1
1865	A thesaurus of genetic variation for interrogation of repetitive genomic regions. 2015 , 43, e68	3
1864	Signatures of accelerated somatic evolution in gene promoters in multiple cancer types. 2015 , 43, 5307-17	27
1863	Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. 2015 , 6, 10131	67
1862	Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. 2015 , 17, 134	47
1861	Partial Histological Tumor Regression in Primary Melanoma as Protective Factor for Lymph Node Micrometastasis. 2015 , 151, 1291-1292	4
1860	Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. 2015 , 7, 1303-11	11
1859	Clusters of Multiple Mutations: Incidence and Molecular Mechanisms. 2015 , 49, 243-67	75
1858	Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. 2015 , 6, 8866	139
1857	The immortality two-step. 2015 , 14, 798	1
1856	The Evolution of Tumors in Mice and Humans with Germline p53 Mutations. 2015 , 80, 139-45	11
1855	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. 2015 , 7, 232-241	

1854	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. 2015 , 357, 179-185	68
1853	Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. 2015 , 64, 99-104	29
1852	Pharmacological reactivation of p53 as a strategy to treat cancer. 2015 , 277, 248-259	56
1851	The genetic landscape of diffuse large B-cell lymphoma. 2015 , 52, 67-76	125
1850	Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. 2015 , 41, 129-35	14
1849	An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. 2015 , 16, 232-41	51
1848	A Big Bang model of human colorectal tumor growth. 2015 , 47, 209-16	646
1847	Incorporating computational resources in a cancer research program. 2015 , 134, 467-78	1
1846	Unfolding the mutational landscape of human melanoma. 2015 , 135, 659-662	16
1845	Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. 2015 , 137, 776-83	33
1844	MADGiC: a model-based approach for identifying driver genes in cancer. 2015 , 31, 1526-35	18
1843	Genetic lesions in diffuse large B-cell lymphomas. 2015 , 26, 1069-1080	52
1842	Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. 2015 , 27, 298-311	183
1841	Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. 2015 , 64, 842-8	124
1840	The genetics of splicing in neuroblastoma. 2015 , 5, 380-95	13
1839	Cell-of-origin chromatin organization shapes the mutational landscape of cancer. <i>Nature</i> , 2015 , 518, 360-364	344
1838	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. 2015 , 6, 5973	128
1837	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. 2015 , 26, 812-817	202

1836	Decreased mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. 2015 , 2, 255-263	74
1835	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. 2015 , 25, 316-27	240
1834	Melanomagenesis: multifaceted attacks on the genome. 2015 , 24, 175-6	3
1833	Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. 2015 , 112, 1107-12	112
1832	Molecular and genetic properties of tumors associated with local immune cytolytic activity. 2015 , 160, 48-61	1834
1831	Rapid and convergent evolution in the glioblastoma multiforme genome. 2015 , 105, 159-67	6
1830	De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry. 2015 , 235, 3-13	95
1829	Novel insights into head and neck cancer using next-generation "omic" technologies. 2015 , 75, 480-6	42
1828	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015 , 518, 495-501	50.4 1579
1827	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. 2015 , 107,	72
1826	APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. 2015 , 112, 2841-6	95
1825	The reverse evolution from multicellularity to unicellularity during carcinogenesis. 2015 , 6, 6367	79
1824	The shortest path is not the one you know: application of biological network resources in precision oncology research. 2015 , 30, 191-204	23
1823	Differential DNA mismatch repair underlies mutation rate variation across the human genome. <i>Nature</i> , 2015 , 521, 81-4	50.4 224
1822	Genomic analysis of metastatic cutaneous squamous cell carcinoma. 2015 , 21, 1447-56	179
1821	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. 2015 , 21, 3631-9	183
1820	Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. 2015 , 17, 15	22
1819	Translational implications of tumor heterogeneity. 2015 , 21, 1258-66	292

1818	The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. 2015 , 16, 225-38	889
1817	Concepts in solid tumor evolution. 2015 , 31, 208-14	38
1816	Genomic analysis of smoothed inhibitor resistance in basal cell carcinoma. 2015 , 27, 327-41	241
1815	Computational cancer biology: education is a natural key to many locks. 2015 , 15, 7	6
1814	Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations. 2015 , 7, 6	6
1813	In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. 2015 , 27, 382-96	237
1812	Roles for Synonymous Codon Usage in Protein Biogenesis. 2015 , 44, 143-66	169
1811	Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. 2015 , 160, 1246-60	544
1810	Genomic Classification of Cutaneous Melanoma. 2015 , 161, 1681-96	1807
1809	Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. 2015 , 126, 508-19	142
1808	Epigenetic reduction of DNA repair in progression to gastrointestinal cancer. 2015 , 7, 30-46	18
1807	Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps. 2015 , 4, e160	90
1806	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. 2015 , 16, 1111-1122	347
1805	Radiogenomics: what it is and why it is important. 2015 , 12, 862-6	158
1804	Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges. 2015 , 16, 1149-60	11
1803	Systematic Screening of Promoter Regions Pinpoints Functional Cis-Regulatory Mutations in a Cutaneous Melanoma Genome. 2015 , 13, 1218-26	24
1802	p53 family members - important messengers in cell death signaling in photodynamic therapy of cancer?. 2015 , 14, 1390-6	21
1801	Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data. 2015 , 31, 3561-8	30

1800	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. 2015 , 47, 996-1002	261
1799	TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. 2015 , 43, 6945-58	37
1798	Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. 2015 , 51, 2086-94	36
1797	Disruption of Transcriptional Coactivator Sub1 Leads to Genome-Wide Re-distribution of Clustered Mutations Induced by APOBEC in Active Yeast Genes. 2015 , 11, e1005217	37
1796	Genetic Intratumor Heterogeneity. 2015 , 571-593	1
1795	Genome-wide association study of colorectal cancer identifies six new susceptibility loci. 2015 , 6, 7138	106
1794	Inflammation and Lung Cancer. 2015 ,	0
1793	Evaluation and integration of cancer gene classifiers: identification and ranking of plausible drivers. 2015 , 5, 10204	15
1792	The Hippo signal transduction pathway in soft tissue sarcomas. 2015 , 1856, 121-9	23
1791	Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. 2015 , 21, 946-54	127
1790	Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. 2015 , 149, 1153-1162.e3	250
1789	Paired exome analysis of Barrett's esophagus and adenocarcinoma. 2015 , 47, 1047-55	232
1788	Genomic landscape of cutaneous T cell lymphoma. 2015 , 47, 1011-9	247
1787	Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. 2015 , 21, 4709-18	35
1786	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. 2015 , 51, 1803-11	26
1785	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015 , 526, 519-24	50.4 565
1784	Precision medicine for metastatic breast cancer—limitations and solutions. 2015 , 12, 693-704	201
1783	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. 2015 , 17, 385-99	156

1782	Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations. 2015 , 75, 3292-301		14
1781	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015 , 524, 47-53	50.4	1061
1780	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. 2015 , 372, 2481-98		1828
1779	Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma. 2015 , 24, 1222-8		11
1778	APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. 2015 , 5, 704-12		267
1777	Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. 2015 , 7, 1037-51		6
1776	Targeted therapies in advanced differentiated thyroid cancer. 2015 , 41, 690-8		43
1775	Genomic alterations in lung adenocarcinoma. 2015 , 16, e342-51		199
1774	Protein domain-level landscape of cancer-type-specific somatic mutations. 2015 , 11, e1004147		46
1773	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. 2015 , 20, 812-22		148
1772	Targeting cancer with kinase inhibitors. 2015 , 125, 1780-9		284
1771	Biology of Ewing sarcoma. 2015 , 245-255		
1770	Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. 2015 , 96, 597-611		222
1769	Melanoma brain metastasis is independent of lactate dehydrogenase A expression. 2015 , 17, 1374-85		9
1768	Cancer vaccines. 2015 , 350, h988		156
1767	Genomics in acute lymphoblastic leukaemia: insights and treatment implications. 2015 , 12, 344-57		189
1766	Adoptive cell transfer as personalized immunotherapy for human cancer. 2015 , 348, 62-8		1420
1765	Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. 2015 , 75, 1567-79		180

1764 Immunostimulation durch Checkpoint-inhibition. **2015**, 18, 31-34

1763 Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. **2015**, 15, 647-64 32

1762 Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. **2015**, 17, 8 57

1761 Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. **2015**, 16, 45 101

1760 Hypermutation takes the driver's seat. **2015**, 7, 31 14

1759 The dJ/dS Ratio Test Reveals Hundreds of Novel Putative Cancer Drivers. **2015**, 32, 2181-5 5

1758 The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. **2015**, 47, 672-6 113

1757 Annotation of Sequence Variants in Cancer Samples: Processes and Pitfalls for Routine Assays in the Clinical Laboratory. **2015**, 17, 339-51 7

1756 BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. **2015**, 13, 122 55

1755 Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. **2015**, 348, 124-8 5003

1754 Small cell lung cancer: will recent progress lead to improved outcomes?. **2015**, 21, 2244-55 129

1753 Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. **2015**, 100, E493-502 110

1752 Research in Computational Molecular Biology. **2015**, 3

1751 The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. **2015**, 47, 330-7 303

1750 Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. **2015**, 6, 6336 85

1749 Management of Pancreatic Neuroendocrine Tumors. **2015**, 1

1748 Synthetic immunity to break down the bottleneck of cancer immunotherapy. **2015**, 60, 977-985 2

1747 The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. **2015**, 3, 15 47

1746	Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes. 2015 , 6, 7033	22
1745	Melanoma. 2015 , 1, 15003	283
1744	RB and Prognosis in Resected Lung Adenocarcinoma. 2015 , 21, 2418-20	3
1743	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. 2015 , 10, S1-63	102
1742	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. 2015 , 47, 367-372	292
1741	Gene expression. MicroRNA control of protein expression noise. 2015 , 348, 128-32	252
1740	Big Data Biology: Between Eliminative Inferences and Exploratory Experiments. 2015 , 82, 198-218	18
1739	The effects of chromatin organization on variation in mutation rates in the genome. 2015 , 16, 213-23	143
1738	How the environment shapes cancer genomes. 2015 , 27, 71-7	27
1737	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. 2015 , 47, 505-511	956
1736	APOBEC3 genes: retroviral restriction factors to cancer drivers. 2015 , 21, 274-84	72
1735	Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. 2015 , 10, 1082-95	129
1734	Cancer whole-genome sequencing: present and future. 2015 , 34, 5943-50	71
1733	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. 2015 , 15, 302-10	227
1732	Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. 2015 , 75, 2264-71	31
1731	Optimal drug prediction from personal genomics profiles. 2015 , 19, 1264-70	23
1730	Targeted approaches to childhood cancer: progress in drug discovery and development. 2015 , 10, 483-95	2
1729	Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. 2015 , 36, 616-21	57

1728	Mutational landscape and clonal architecture in grade II and III gliomas. 2015 , 47, 458-68	543
1727	Cancer vaccines: can they improve survival?. 2015 , 30, 147-51	6
1726	Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit. 2015 , 36, 937-45	16
1725	Genetics and genomics of psychiatric disease. 2015 , 349, 1489-94	249
1724	The origins, determinants, and consequences of human mutations. 2015 , 349, 1478-83	111
1723	Somatic mutation in cancer and normal cells. 2015 , 349, 1483-9	608
1722	Genomic approaches to DNA repair and mutagenesis. 2015 , 36, 146-155	20
1721	Somatic mutation in single human neurons tracks developmental and transcriptional history. 2015 , 350, 94-98	364
1720	T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. 2015 , 3, 1115-22	121
1719	Harmful somatic amino acid substitutions affect key pathways in cancers. 2015 , 8, 53	12
1718	Integrated molecular analysis of adult T cell leukemia/lymphoma. 2015 , 47, 1304-15	469
1717	Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique. 2015 , 17, 379-389	
1716	Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. 2015 , 21, 1514-20	75
1715	Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. 2015 , 21, 5371-9	19
1714	The Molecular Taxonomy of Primary Prostate Cancer. 2015 , 163, 1011-25	1713
1713	The Personalization of Therapy: Molecular Profiling Technologies and Their Application. 2015 , 42, 775-87	4
1712	The PKC/NF- κ B signaling pathway induces APOBEC3B expression in multiple human cancers. 2015 , 75, 4538-47	87
1711	Practical Approaches to Immunotherapy in the Clinic. 2015 , 42 Suppl 3, S20-7	8

1710	Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer. 2015 , 33, 1521-2	19
1709	Between pathways and networks lies context: implications for precision medicine. 2015 , 98, 253-63	
1708	The path to routine use of genomic biomarkers in the cancer clinic. 2015 , 25, 1508-13	26
1707	T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. 2015 , 28, 638-652	129
1706	Immunogenicity of somatic mutations in human gastrointestinal cancers. 2015 , 350, 1387-90	465
1705	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. 2015 , 1, 197-209	72
1704	Mismatch repair. 2015 , 290, 26395-403	118
1703	Unique ability of pandemic influenza to downregulate the genes involved in neuronal disorders. 2015 , 42, 1377-90	10
1702	Genomic spectra of biliary tract cancer. 2015 , 47, 1003-10	612
1701	An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. 2015 , 47, 1067-72	238
1700	Prospects of immune checkpoint modulators in the treatment of glioblastoma. 2015 , 11, 504-14	240
1699	Mutation signatures implicate aristolochic acid in bladder cancer development. 2015 , 7, 38	63
1698	High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. 2015 , 21, 1318-25	752
1697	Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. 2015 , 21, 4514-24	85
1696	Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. 2015 , 26, 2367-74	33
1695	Mining the coding and non-coding genome for cancer drivers. 2015 , 369, 307-15	9
1694	Comprehensive assessment of cancer missense mutation clustering in protein structures. 2015 , 112, E5486-95	142
1693	Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. 2015 , 16, 193	17

1692	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. 2015 , 6, 6044	120
1691	Genomic landscape of adenoid cystic carcinoma of the breast. 2015 , 237, 179-89	101
1690	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. 2015 , 163, 506-19	1055
1689	Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. 2015 , 42, 713-23	10
1688	Mutations driving CLL and their evolution in progression and relapse. <i>Nature</i> , 2015 , 526, 525-30	50.4 658
1687	Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. 2015 , 6, 8554	71
1686	The mini-driver model of polygenic cancer evolution. 2015 , 15, 680-5	66
1685	Chromothripsis: A New Mechanism for Rapid Karyotype Evolution. 2015 , 49, 183-211	122
1684	LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations. 2015 , 43, 8123-34	48
1683	Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. 2015 , 47, 1149-57	183
1682	Molecular changes in endometriosis-associated ovarian clear cell carcinoma. 2015 , 51, 1831-42	37
1681	TCF12 is mutated in anaplastic oligodendroglioma. 2015 , 6, 7207	32
1680	COSMIC: exploring the world's knowledge of somatic mutations in human cancer. 2015 , 43, D805-11	1795
1679	Strategies for combining immunotherapy with radiation for anticancer therapy. 2015 , 7, 967-980	64
1678	Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. 2015 , 17, 554-9	49
1677	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. 2015 , 314, 913-25	257
1676	Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. 2015 , 30, 187-94	15
1675	Next-generation sequencing: hype and hope for development of personalized radiation therapy?. 2015 , 10, 183	8

1674	Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. 2015 , 21, 4935-46	49
1673	Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma. 2015 , 21, 2613-23	11
1672	Spatiotemporal Evolution of the Primary Glioblastoma Genome. 2015 , 28, 318-28	180
1671	Deciphering associations for lung cancer risk through imputation and analysis of 12,316 cases and 16,831 controls. 2015 , 23, 1723-8	13
1670	Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?. 2015 , 36 Suppl 1, S203-31	61
1669	DIGGIT: a Bioconductor package to infer genetic variants driving cellular phenotypes. 2015 , 31, 4032-4	7
1668	Environmental pollution and DNA methylation: carcinogenesis, clinical significance, and practical applications. 2015 , 9, 261-74	19
1667	Shared and unique mutational gene co-occurrences in cancers. 2015 , 465, 777-83	2
1666	Landscape of Tumor Antigens in T Cell Immunotherapy. 2015 , 195, 5117-22	100
1665	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. 2015 , 41, 868-76	280
1664	Genomic profiling of Sjögren syndrome identifies alterations of key T cell signaling and differentiation genes. 2015 , 47, 1426-34	199
1663	Using prediction markets to estimate the reproducibility of scientific research. 2015 , 112, 15343-7	131
1662	Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. 2015 , 112, E6496-505	236
1661	Exome sequencing reveals mutant genes with low penetrance involved in MEN2A-associated tumorigenesis. 2015 , 22, 23-33	11
1660	Using common variants to indicate cancer genes. 2015 , 136, 241-5	
1659	Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. 2015 , 47, 106-14	547
1658	The landscape and therapeutic relevance of cancer-associated transcript fusions. 2015 , 34, 4845-54	294
1657	Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. 2015 , 15, 25-41	680

1656	A comprehensive transcriptional portrait of human cancer cell lines. 2015 , 33, 306-12	407
1655	Large transcription units unify copy number variants and common fragile sites arising under replication stress. 2015 , 25, 189-200	114
1654	An argument for mechanism-based statistical inference in cancer. 2015 , 134, 479-95	8
1653	The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing. 2015 , 36, 118-28	28
1652	The genomic and functional characteristics of disease genes. 2015 , 16, 16-23	7
1651	Driver and passenger mutations in cancer. 2015 , 10, 25-50	179
1650	Deciphering oncogenic drivers: from single genes to integrated pathways. 2015 , 16, 413-28	20
1649	The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. <i>Nature</i> , 2015 , 517, 489-92	50.4 223
1648	APOBEC3A functions as a restriction factor of human papillomavirus. 2015 , 89, 688-702	113
1647	Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. 2015 , 47, 13-21	247
1646	Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. 2015 , 168, 507-10	36
1645	Defining the genomic landscape of head and neck cancers through next-generation sequencing. 2015 , 21, e11-24	20
1644	Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. 2015 , 21, 632-41	398
1643	Cancer evolution: mathematical models and computational inference. 2015 , 64, e1-25	181
1642	Challenges and opportunities for next-generation sequencing in companion diagnostics. 2015 , 15, 193-209	11
1641	Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. 2015 , 34, 3617-26	165
1640	Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?. 2016 , 5, 980-983	7
1639	Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer. 2016 , 7, 55249-55263	12

1638	Detecting the potential cancer association or metastasis by multi-omics data analysis. 2016 , 15,	7
1637	Institutional implementation of clinical tumor profiling on an unselected cancer population. 2016 , 1, e87062	245
1636	CRISPR/Cas9 and cancer targets: future possibilities and present challenges. 2016 , 7, 12305-17	42
1635	Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. 2016 , 17,	16
1634	High-Throughput Identification of Adaptive Mutations in Experimentally Evolved Yeast Populations. 2016 , 12, e1006339	38
1633	New targeted treatments for non-small-cell lung cancer - role of nivolumab. 2016 , 10, 103-17	18
1632	Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. 2016 , 23, e571-e575	6
1631	Multiple myeloma, immunotherapy and minimal residual disease. 2016 , 63, 651-8	1
1630	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. 2016 , 7, 3403-15	229
1629	PD-L1 expression in lung cancer. 2016 , 8, 3053-3055	1
1628	Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing. 2016 , 5, 271-3	3
1627	CEACAM1: Expression and Role in Melanocyte Transformation. 2016 , 2016, 9406319	5
1626	Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells. 2016 , 2016, 6891482	21
1625	A Survey of Computational Tools to Analyze and Interpret Whole Exome Sequencing Data. 2016 , 2016, 7983236	23
1624	Immune Cells in Cancer Therapy and Drug Delivery. 2016 , 2016, 5230219	23
1623	ROMA: Representation and Quantification of Module Activity from Target Expression Data. 2016 , 7, 18	25
1622	DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders. 2016 , 6, 187	29
1621	Cancer Vaccines in Ovarian Cancer: How Can We Improve?. 2016 , 4,	38

1620	Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. 2016 , 17,	24
1619	Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. 2016 , 17,	35
1618	Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment. 2016 , 17,	19
1617	ODMedit: uniform semantic annotation for data integration in medicine based on a public metadata repository. 2016 , 16, 65	22
1616	Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma. 2016 , 16, 646	5
1615	[Cooperation between a somatic mutation and a genetic susceptibility variant in Ewing sarcoma]. 2016 , 32, 323-6	0
1614	Identifying Network Perturbation in Cancer. 2016 , 12, e1004888	26
1613	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. 2016 , 13, e1002136	25
1612	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. 2016 , 13, e1002201	214
1611	Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces. 2016 , 11, e0152929	56
1610	Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes. 2016 , 11, e0153433	7
1609	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. 2016 , 11, e0155189	77
1608	Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration. 2016 , 11, e0165371	22
1607	Use of "omics" technologies to dissect neurologic disease. 2016 , 138, 91-106	4
1606	The Role of Immunotherapy in Multiple Myeloma. 2016 , 9,	19
1605	Delayed Onset of Symptoms Through Feedback Interference in Chronic Cancers. 2016 , 2,	1
1604	Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. 2016 , 7, 17194-211	62
1603	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. 2016 , 7, 73068-73079	60

1602	Distinct genetic profiles of extracranial and intracranial acral melanoma metastases. 2016 , 43, 884-91	2
1601	Exome-based proteogenomics of HEK-293 human cell line: Coding genomic variants identified at the level of shotgun proteome. 2016 , 16, 1980-91	18
1600	Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer. 2016 , 24, 121-7	16
1599	Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy. 2016 , 65, 995-1002	9
1598	Biology of lung cancer: genetic mutation, epithelial-mesenchymal transition, and cancer stem cells. 2016 , 64, 517-23	13
1597	Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 Levels. 2016 , 16, 672-83	19
1596	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. 2016 , 63, 201-17	265
1595	Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. 2016 , 2, e70	19
1594	mutation3D: Cancer Gene Prediction Through Atomic Clustering of Coding Variants in the Structural Proteome. 2016 , 37, 447-56	51
1593	Variation Interpretation Predictors: Principles, Types, Performance, and Choice. 2016 , 37, 579-97	75
1592	Immunotherapy in colorectal cancer: What have we learned so far?. 2016 , 460, 78-87	9
1591	The Doppelgänger Effect: Hidden Duplicates in Databases of Transcriptome Profiles. 2016 , 108,	8
1590	A Landscape of Pharmacogenomic Interactions in Cancer. 2016 , 166, 740-754	892
1589	Discovering potential cancer driver genes by an integrated network-based approach. 2016 , 12, 2921-31	22
1588	Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/βcatenin signaling pathway mutations. 2016 , 122, 1689-96	17
1587	Single-cell profiling approaches to probing tumor heterogeneity. 2016 , 139, 243-55	42
1586	Recent advances in immuno-oncology and its application to urological cancers. 2016 , 118, 506-14	11
1585	Applying CRISPR-Cas9 tools to identify and characterize transcriptional enhancers. 2016 , 17, 597-604	42

1584	The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation. 2016 , 6,	25
1583	Mutation at a distance caused by homopolymeric guanine repeats in <i>Saccharomyces cerevisiae</i> . 2016 , 2, e1501033	2
1582	Distinct mutation accumulation rates among tissues determine the variation in cancer risk. 2016 , 6, 19458	13
1581	Composition and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Disease. 2016 , 81, 53-60	57
1580	Cancer Bioinformatics. 2016 , 1-14	
1579	Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma. 2016 , 17, 125	53
1578	Genomic evolution and chemoresistance in germ-cell tumours. <i>Nature</i> , 2016 , 540, 114-118	50.4 100
1577	Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas. 2016 , 8, 74	3
1576	Philosophy of Molecular Medicine. 2016 ,	6
1575	Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. 2016 , 17 Suppl 2, 394	21
1574	Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data. 2016 , 17, 341	60
1573	Cell type-specific properties and environment shape tissue specificity of cancer genes. 2016 , 6, 20707	50
1572	The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. 2016 , 8, 442-57	154
1571	Integrative Genomics and Transcriptomics Analysis Reveals Potential Mechanisms for Favorable Prognosis of Patients with HPV-Positive Head and Neck Carcinomas. 2016 , 6, 24927	19
1570	Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours. 2016 , 7, 11588	19
1569	An integrated analysis of cancer genes in thyroid cancer. 2016 , 35, 962-70	17
1568	How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?. 2016 , 81, 247-255	13
1567	Driver gene classification reveals a substantial overrepresentation of tumor suppressors among very large chromatin-regulating proteins. 2016 , 6, 38988	16

1566	Divergent viral presentation among human tumors and adjacent normal tissues. 2016 , 6, 28294	44
1565	Insights into the role of NRF2 in cancer provided by cancer genomics. 2016 , 1, 111-117	6
1564	iCAGES: integrated CANcer GENome Score for comprehensively prioritizing driver genes in personal cancer genomes. 2016 , 8, 135	31
1563	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. 2016 , 108,	44
1562	Dendritic cell vaccines for melanoma: past, present and future. 2016 , 3, 273-289	12
1561	Dog Models of Naturally Occurring Cancer. 2016 , 153-221	5
1560	When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. 2016 , 128, 2381-2387	40
1559	Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. 2016 , 5, e273	17
1558	A weighted exact test for mutually exclusive mutations in cancer. 2016 , 32, i736-i745	37
1557	PDX ou xBogreffe d'ivB de la tumeur du patient, la renaissance d'un modEe oubliE son implication dans la recherche et la clinique de demain. 2016 , 4, 237-245	0
1556	A Pipeline for Drug Target Identification and Validation. 2016 , 81, 257-267	11
1555	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. 2016 , 6, 19552	20
1554	Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. 2016 , 6, 25264	49
1553	Exploration of regression models for cancer noncoding mutation recurrence. 2016 ,	1
1552	Enhanced gene targeting to evaluate Lynch syndrome alterations. 2016 , 113, 3918-20	0
1551	Immunotherapy for genitourinary malignancies in the here and now!. 2016 , 34, 169-70	
1550	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. 2016 , 58, 59-70	78
1549	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. 2016 , 27, 1443-8	53

1548	Targeting neoantigens for cancer immunotherapy. 2016 , 28, 365-70	37
1547	Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure. 2016 , 76, 3719-31	61
1546	Biased Expression of the FOXP3 β Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. 2016 , 22, 5349-5361	14
1545	Genomic Landscape of Colorectal Mucosa and Adenomas. 2016 , 9, 417-27	58
1544	[Systemic treatment of inoperable metastasized malignant melanoma]. 2016 , 67, 529-35	
1543	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. 2016 , 76, 3767-72	98
1542	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). 2016 , 27, 1492-504	280
1541	Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis. 2016 , 98, 709-27	95
1540	The Complete Genome Sequences, Unique Mutational Spectra, and Developmental Potency of Adult Neurons Revealed by Cloning. 2016 , 89, 1223-1236	69
1539	Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. 2016 , 9, 41-54	4
1538	Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. 2016 , 25, 1875-84	70
1537	Do cell-autonomous and non-cell-autonomous effects drive the structure of tumor ecosystems?. 2016 , 1865, 147-54	6
1536	Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. 2016 , 140, 249-54	69
1535	Cancer genomics: Hard-to-reach repairs. <i>Nature</i> , 2016 , 532, 181-2	50.4 4
1534	Nucleotide excision repair is impaired by binding of transcription factors to DNA. <i>Nature</i> , 2016 , 532, 264-70.4	192
1533	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. 2016 , 16, 275-87	1444
1532	Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma. 2016 , 11, 344-53	8
1531	The role of neoantigens in response to immune checkpoint blockade. 2016 , 28, 411-9	88

1530	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. 2016 , 30, 1672-81	65
1529	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines. 2016 , 95, e3134	12
1528	Characterizing genomic alterations in cancer by complementary functional associations. 2016 , 34, 539-46	57
1527	Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. 2016 , 17, 350-361	83
1526	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. 2016 , 374, 2542-52	828
1525	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. 2016 , 22, 4623-33	114
1524	WeSME: uncovering mutual exclusivity of cancer drivers and beyond. 2017 , 33, 814-821	41
1523	Cancer immunotherapy: the beginning of the end of cancer?. 2016 , 14, 73	651
1522	Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. 2016 , 29, 737-750	31
1521	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. 2016 , 29, 723-736	324
1520	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. 2016 , 48, 607-16	613
1519	Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. 2016 , 6, 714-26	100
1518	Re-Evaluating Clonal Dominance in Cancer Evolution. 2016 , 2, 263-276	33
1517	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016 , 534, 47-54	1193
1516	[Renaissance of immuno-oncology for urological tumors : Current status]. 2016 , 55, 621-6	2
1515	Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing. 2016 , 98, 843-856	27
1514	Recent developments in the use of immunotherapy in non-small cell lung cancer. 2016 , 10, 781-98	23
1513	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. 2016 , 48, 600-606	238

1512	Oesophageal adenocarcinoma and gastric cancer: should we mind the gap?. 2016 , 16, 305-18	77
1511	International cancer seminars: a focus on kidney cancer. 2016 , 27, 1382-5	11
1510	Impacts of somatic mutations on gene expression: an association perspective. 2017 , 18, 413-425	26
1509	Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. 2016 , 29, 622-637	160
1508	Zebrafish Melanoma. 2016 , 916, 439-50	4
1507	Controllability of the better chosen partial networks. 2016 , 456, 120-127	3
1506	Targetable genetic features of primary testicular and primary central nervous system lymphomas. 2016 , 127, 869-81	317
1505	A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. 2016 , 6, e467	47
1504	An analytical workflow for accurate variant discovery in highly divergent regions. 2016 , 17, 703	12
1503	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. 2016 , 48, 1131-41	233
1502	Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. 2016 , 46, 935-941	45
1501	Pediatric soft tissue tumor pathology: A happy morpho-molecular union. 2016 , 33, 377-395	3
1500	SHP-1: the next checkpoint target for cancer immunotherapy?. 2016 , 44, 356-62	31
1499	Biomarkers in Melanoma: Lessons from Translational Medicine. 2016 , 2, 305-312	6
1498	ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome. 2016 , 175, R203-17	33
1497	Propolis extracts from the northern region of Thailand suppress cancer cell growth through induction of apoptosis pathways. 2016 , 34, 707-722	16
1496	The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process. 2016 , 50, 347-369	57
1495	Computational Prediction of Genetic Drivers in Cancer. 2016 , 1-16	4

1494	[Update on molecular classifications and new histological classification of bladder cancer]. 2016 , 26, 600-607	1
1493	Genomic Aberrations in Multiple Myeloma. 2016 , 169, 23-34	10
1492	WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. 2016 , 243, 21-28	3
1491	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. 2016 , 113, 12238-12243	123
1490	Big Data Analytics. 2016 ,	6
1489	Approaches for targeting cancer stem cells drug resistance. 2016 , 11, 1201-1212	23
1488	Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. 2016 , 1, 12	13
1487	Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. 2016 , 11, 2723-2734	59
1486	Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. 2016 , 5, e1238539	16
1485	Identifying cancer type specific oncogenes and tumor suppressors using limited size data. 2016 , 14, 1650031	6
1484	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. 2016 , 12, 105-117	169
1483	Chromatin structure-based prediction of recurrent noncoding mutations in cancer. 2016 , 48, 1321-1326	21
1482	The genomic landscape of schwannoma. 2016 , 48, 1339-1348	74
1481	Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. 2016 , 65, 91-101	186
1480	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. 2016 , 61, 152-8	40
1479	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. 2016 , 8, 1011-9	28
1478	PathScore: a web tool for identifying altered pathways in cancer data. 2016 , 32, 3688-3690	3
1477	Clinical Outcomes of TP53 Mutations in Cancers. 2016 , 6,	35

1476	Dual Chromatin and Cytoskeletal Remodeling by SETD2. 2016 , 166, 950-962	128
1475	An Efficient Branch and Cut Algorithm to Find Frequently Mutated Subnetworks in Cancer. 2016 , 27-39	3
1474	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. 2016 , 5, 2567-78	45
1473	Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5. 2016 , 12, 1776-1790	20
1472	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. 2016 , 122, 1836-43	25
1471	High-throughput Phenotyping of Lung Cancer Somatic Mutations. 2016 , 30, 214-228	119
1470	Chromosomal landscape of UV damage formation and repair at single-nucleotide resolution. 2016 , 113, 9057-62	83
1469	Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. 2016 , 175, 476-489	42
1468	The genomic landscape of cutaneous melanoma. 2016 , 29, 266-83	100
1467	Translating cancer genomes and transcriptomes for precision oncology. 2016 , 66, 75-88	108
1466	Sources and consequences of oxidative damage from mitochondria and neurotransmitter signaling. 2016 , 57, 322-30	5
1465	The genomic landscape of epithelioid sarcoma cell lines and tumours. 2016 , 238, 63-73	27
1464	Immunotherapy for bladder cancer: rediscovering an old friend. 2016 , 117, 721-4	
1463	Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. 2016 , 37, 13413-13423	17
1462	Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. 2016 , 48, 1260-6	53
1461	Genomics Study of Gastric Cancer and Its Molecular Subtypes. 2016 , 908, 419-39	9
1460	Deep Genetic Connection Between Cancer and Developmental Disorders. 2016 , 37, 1042-50	10
1459	A comprehensive genomic characterization of esophageal squamous cell carcinoma: from prognostic analysis to in vivo assay. 2016 , 35, 76	5

1458	State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. 2016 , 66, 460-480	93
1457	BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis. 2016 , 186, 2551-4	2
1456	Genetic evolution in chronic lymphocytic leukaemia. 2016 , 29, 67-78	1
1455	Inheritance-mode specific pathogenicity prioritization (ISPP) for human protein coding genes. 2016 , 32, 3065-3071	8
1454	An Evolutionary Genetic Perspective on Cancer Biology. 2016 , 47, 25-49	6
1453	Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy!. 2016 , 122, 3263-3266	2
1452	A new correlation clustering method for cancer mutation analysis. 2016 , 32, 3717-3728	10
1451	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. 2016 , 8, 360-74	33
1450	Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. 2016 , 34, 538-547	28
1449	Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers. 2016 , 7, 13418	28
1448	Evaluating the evaluation of cancer driver genes. 2016 , 113, 14330-14335	197
1447	Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. 2016 , 6, 1342-1351	116
1446	Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. 2016 , 16, 653	26
1445	MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. 2016 , 17, 178	120
1444	Biologic and Clinical Perspectives on Thyroid Cancer. 2016 , 375, 1054-67	405
1443	Leveraging premalignant biology for immune-based cancer prevention. 2016 , 113, 10750-8	44
1442	Development of prognostic signatures for intermediate-risk papillary thyroid cancer. 2016 , 16, 736	16
1441	Whole-exome sequencing identifies multiple loss-of-function mutations of NF- κ B pathway regulators in nasopharyngeal carcinoma. 2016 , 113, 11283-11288	107

1440	Unsupervised detection of cancer driver mutations with parsimony-guided learning. 2016 , 48, 1288-94	33
1439	Mutational patterns in oncogenes and tumour suppressors. 2016 , 44, 925-31	11
1438	Candidate driver genes involved in genome maintenance and DNA repair in Sjögren syndrome. 2016 , 127, 3387-97	71
1437	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. 2016 , 9, 89-104	113
1436	Preferential Protection of Genetic Fidelity within Open Chromatin by the Mismatch Repair Machinery. 2016 , 291, 17692-705	17
1435	Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. 2016 , 5, 128-38	80
1434	[Melanoma brain metastases : Treatment options]. 2016 , 67, 536-43	4
1433	Findings made in gene panel to whole genome sequencing: data, knowledge, ethics - and consequences?. 2016 , 16, 1259-1270	11
1432	Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing. 2016 , 99, 1190-1198	99
1431	Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events. 2016 , 7, 13197	41
1430	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. 2016 , 1, e000022	13
1429	Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology. 2016 , 49, 2088-2104	3
1428	Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. 2016 , 7, 11938	95
1427	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. 2016 , 17, 231	391
1426	Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. 2016 , 7, 12619	111
1425	Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. 2016 , 6, 26483	15
1424	Challenges in identifying cancer genes by analysis of exome sequencing data. 2016 , 7, 12096	27
1423	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. 2016 , 6, 27702	38

1422	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. 2016 , 113, E7769-E7777	116
1421	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. 2016 , 7, 11111	54
1420	Inactivation of TGF β receptors in stem cells drives cutaneous squamous cell carcinoma. 2016 , 7, 12493	63
1419	Genome-wide significance testing of variation from single case exomes. 2016 , 48, 1455-1461	30
1418	Computational pan-genomics: status, promises and challenges. 2018 , 19, 118-135	130
1417	Big Data Analytics in Genomics. 2016 ,	4
1416	Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations. 2016 , 76, 6785-6794	3
1415	Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop. 2016 , 102, 147-79	1
1414	The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis. 2016 , 6, 35770	14
1413	SSA-ME Detection of cancer driver genes using mutual exclusivity by small subnetwork analysis. 2016 , 6, 36257	9
1412	Classification of breast cancer patients using somatic mutation profiles and machine learning approaches. 2016 , 10 Suppl 3, 62	34
1411	PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. 2016 , 9, 201-206	28
1410	Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. 2016 , 2, 16025	52
1409	Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. 2016 , 8, 55	31
1408	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. 2016 , 7, 12602	102
1407	The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. 2016 , 7, 12918	107
1406	Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. 2016 , 113, 10672-7	31
1405	The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. 2016 , 7, 11479	779

1404	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. 2016 , 7, 11815	409
1403	Cancer driver gene discovery through an integrative genomics approach in a non-parametric Bayesian framework. 2017 , 33, 483-490	10
1402	NGS Analysis of Somatic Mutations in Cancer Genomes. 2016 , 357-372	
1401	Big Data and Cancer Research. 2016 , 259-276	1
1400	Circulating Biomarkers in Bladder Cancer. 2016 , 2, 369-379	24
1399	Hirnmetastasen beim malignen Melanom. 2016 , 42, 501-506	
1398	Integrating cancer genomic data into electronic health records. 2016 , 8, 113	41
1397	Predicting the recurrence of noncoding regulatory mutations in cancer. 2016 , 17, 492	5
1396	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. 2016 , 16, 692	23
1395	Cancer somatic mutations cluster in a subset of regulatory sites predicted from the ENCODE data. 2016 , 15, 76	3
1394	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report. 2016 , 95, e5447	12
1393	Immunotherapy for prostate cancer: is prostate an immune responsive tumor?. 2016 , 26, 529-34	7
1392	Genomic Classification and Prognosis in Acute Myeloid Leukemia. 2016 , 374, 2209-2221	1999
1391	Progress in Cancer Immunotherapy. 2016 ,	5
1390	The SIOPE strategic plan: A European cancer plan for children and adolescents. 2016 , 8, 17-32	34
1389	Blockade von Immuncheckpoints. 2016 , 31, 226-229	
1388	Recurrent genetic defects in classical Hodgkin lymphoma cell lines. 2016 , 57, 2890-2900	9
1387	Discovering and understanding oncogenic gene fusions through data intensive computational approaches. 2016 , 44, 4487-503	88

1386	Systematic analysis of somatic mutations driving cancer: uncovering functional protein regions in disease development. 2016 , 11, 23	11
1385	Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma. 2016 , 5, 1	47
1384	Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology. 2016 , 4,	9
1383	pathTiME _x : Joint Inference of Mutually Exclusive Cancer Pathways and Their Dependencies in Tumor Progression. 2016 , 65-82	1
1382	Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. 2016 , 113, E3892-900	76
1381	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. 2016 , 13, 420-31	66
1380	MUFFINN: cancer gene discovery via network analysis of somatic mutation data. 2016 , 17, 129	85
1379	Long noncoding RNAs in cancer: mechanisms of action and technological advancements. 2016 , 15, 43	308
1378	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. 2016 , 12, 1805-22	6
1377	Development and clinical application of an integrative genomic approach to personalized cancer therapy. 2016 , 8, 62	58
1376	Immunotherapy for advanced melanoma: Current knowledge and future directions. 2016 , 83, 87-94	12
1375	Understanding Intratumoral Heterogeneity: Lessons from the Analysis of At-Risk Tissue and Premalignant Lesions in the Colon. 2016 , 9, 638-41	12
1374	Genome Stability Requires p53. 2016 , 6,	59
1373	When Genome Maintenance Goes Badly Awry. 2016 , 62, 777-87	51
1372	IL-10 and integrin signaling pathways are associated with head and neck cancer progression. 2016 , 17, 38	30
1371	A comprehensive survey of the mutagenic impact of common cancer cytotoxics. 2016 , 17, 99	117
1370	OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. 2016 , 17, 128	143
1369	SMT and TOFT: Why and How They are Opposite and Incompatible Paradigms. 2016 , 64, 221-39	15

1368	Protein-structure-guided discovery of functional mutations across 19 cancer types. 2016 , 48, 827-37	88
1367	BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. 2016 , 95, 1211-21	46
1366	The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. 2016 , 13, 409-19	65
1365	Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma. 2016 , 22, 4356-65	55
1364	Malignant pheochromocytomas/paragangliomas harbor mutations in transport and cell adhesion genes. 2016 , 138, 2201-11	17
1363	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. 2016 , 166, 9-29	22
1362	Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. 2016 , 30, 2179-2186	51
1361	Algorithmic methods to infer the evolutionary trajectories in cancer progression. 2016 , 113, E4025-34	49
1360	The role of enhancers in cancer. 2016 , 16, 483-93	201
1359	Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer. 2016 , 5, e947175	1
1358	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. 2016 , 3, e1048929	24
1357	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. 2016 , 4, 3	146
1356	Immunotherapy for advanced melanoma: future directions. 2016 , 8, 199-209	14
1355	Precision Therapy for Pediatric Cancers. 2016 , 2, 575-577	4
1354	The kinome 'at large' in cancer. 2016 , 16, 83-98	167
1353	Reply: Co-occurrence of MYC amplification and TP53 mutations in human cancer. 2016 , 48, 106-8	1
1352	Genomic characterization of primary central nervous system lymphoma. 2016 , 131, 865-75	96
1351	Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. 2016 , 164, 538-49	239

1350	Pembrolizumab for the treatment of non-small cell lung cancer. 2016 , 16, 397-406	52
1349	Comparison of the fecal microbiota of dholes high-throughput Illumina sequencing of the V3-V4 region of the 16S rRNA gene. 2016 , 100, 3577-86	73
1348	Role of non-coding sequence variants in cancer. 2016 , 17, 93-108	301
1347	Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. 2016 , 1863, 471-482	67
1346	Search for new loci and low-frequency variants influencing glioma risk by exome-array analysis. 2016 , 24, 717-24	5
1345	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. 2016 , 34, 91-101	107
1344	Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. 2016 , 12, 102-8	51
1343	Coordination of DNA damage tolerance mechanisms with cell cycle progression in fission yeast. 2016 , 15, 261-73	6
1342	An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types. 2016 , 32, 1643-51	14
1341	Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. 2016 , 468, 313-9	42
1340	Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. 2016 , 12, 9-23	11
1339	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. 2016 , 8, 479-88	105
1338	Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. 2016 , 29, 394-406	81
1337	Evaluating replicability of laboratory experiments in economics. 2016 , 351, 1433-6	493
1336	Integrative clustering methods of multi-omics data for molecule-based cancer classifications. 2016 , 4, 58-67	37
1335	Emerging Molecular Targets in the Treatment of Head and Neck Squamous Cell Carcinoma. 2016 , 163-209	
1334	Does transcription-associated DNA damage limit lifespan?. 2016 , 41, 1-7	12
1333	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. 2016 , 14, 907-919	75

1332	NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings. 2016 , 44, D992-9	77
1331	Network-Based Method for Inferring Cancer Progression at the Pathway Level from Cross-Sectional Mutation Data. 2016 , 13, 1036-1044	6
1330	Mutation pattern is an influential factor on functional mutation rates in cancer. 2015 , 16, 2	2
1329	Cellular and molecular aspects of pancreatic cancer. 2016 , 118, 305-16	23
1328	Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability. 2016 , 76, 1724-32	86
1327	Novel therapies for advanced squamous cell carcinoma of the lung. 2016 , 12, 659-67	8
1326	An expanded sequence context model broadly explains variability in polymorphism levels across the human genome. 2016 , 48, 349-55	102
1325	APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. 2016 , 33, 26	15
1324	Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. 2016 , 11, 283-312	72
1323	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. 2016 , 22, 298-305	775
1322	Early and multiple origins of metastatic lineages within primary tumors. 2016 , 113, 2140-5	95
1321	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. 2016 , 22, 2261-70	164
1320	Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better?. 2016 , 34, 521-3	6
1319	JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. 2016 , 30, 1311-9	93
1318	Research methods to change clinical practice for patients with rare cancers. 2016 , 17, e70-e80	75
1317	Grundlagen der malignen Transformation. 2016 , 22, 5-12	
1316	The three-dimensional cancer genome. 2016 , 36, 1-7	44
1315	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. 2016 , 22, 262-9	533

1314	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. 2016 , 22, 3182-91	67
1313	The Genomic Landscape of Male Breast Cancers. 2016 , 22, 4045-56	85
1312	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016 , 531, 47-52	50.4 1785
1311	Systematic Prioritization of Druggable Mutations in ~5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach. 2016 , 15, 642-56	38
1310	Die medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms. 2016 , 13, 65-74	
1309	APOBEC3A damages the cellular genome during DNA replication. 2016 , 15, 998-1008	51
1308	The possibility of clinical sequencing in the management of cancer. 2016 , 46, 399-406	24
1307	Genetics of Osteosarcoma. 2016 , 3-17	1
1306	Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. 2016 , 4, 452-62	62
1305	Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. 2016 , 48, 407-16	497
1304	Targeting Oral Cancer. 2016 ,	
1303	Clinical impact of tumour biology in the management of gastroesophageal cancer. 2016 , 13, 348-60	100
1302	MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations. 2016 , 98, 442-455	23
1301	Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. 2016 , 24, 1078-1089	43
1300	Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. 2016 , 48, 398-406	242
1299	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. 2016 , 16, 170	24
1298	[YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?]. 2016 , 55, 356-63	1
1297	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. 2016 , 98, 122-36	17

1296	Translating gastric cancer genomics into targeted therapies. 2016 , 100, 141-6	35
1295	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. 2016 , 22, 1364-70	182
1294	Emerging immunotherapy for the treatment of esophageal cancer. 2016 , 25, 667-77	21
1293	Adoptive T-Cell Therapy for Cancer. 2016 , 130, 279-94	126
1292	On the Sample Complexity of Cancer Pathways Identification. 2016 , 23, 30-41	5
1291	Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. 2016 , 48, 117-25	60
1290	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. 2016 , 22, 793-801	43
1289	Beyond the exome: the role of non-coding somatic mutations in cancer. 2016 , 27, 240-8	24
1288	Apoptotic vesicles as tumor vaccine. 2016 , 8, 5-8	2
1287	APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. 2016 , 26, 174-82	110
1286	Cancer immunotherapy targeting neoantigens. 2016 , 28, 22-7	153
1285	Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. 2016 , 890, 123-36	31
1284	Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. 2016 ,	1
1283	Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. 2016 , 108,	36
1282	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. 2016 , 37, 141-153	19
1281	Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. 2016 , 22, 2237-49	60
1280	"Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. 2016 , 98, 3-18	317
1279	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 2016 , 34, 155-63	465

1278	Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression. 2016 , 14, 196-206	16
1277	Metastatic melanoma treatment: Combining old and new therapies. 2016 , 98, 242-53	55
1276	Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine. 2016 , 16, 25-38	23
1275	Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. 2016 , 16, 13-20	51
1274	Novel Treatments in Development for Melanoma. 2016 , 167, 371-416	10
1273	RETRACTED ARTICLE: Targeted DNA methylation analysis explores association of adenocarcinoma and neuroendocrine epitypes with lung cancer. 2016 , 37, 2537	
1272	Immune checkpoint inhibitors: a new frontier in bladder cancer. 2016 , 34, 49-55	11
1271	Murine melanomas accelerated by a single UVR exposure carry photoproduct footprints but lack UV signature C>T mutations in critical genes. 2016 , 35, 3342-50	16
1270	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. 2016 , 150, 48-63	71
1269	Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. 2016 , 35, 3092-102	15
1268	The Immunotherapy Roadmap. 2016 , 22, 275-6	2
1267	The influence of subclonal resistance mutations on targeted cancer therapy. 2016 , 13, 335-47	139
1266	Personalized approaches to active immunotherapy in cancer. 2016 , 1865, 72-82	30
1265	Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. 2016 , 35, 2413-27	293
1264	Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. 2016 , 17, 642-56	83
1263	Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer. 2016 , 15, 54-66	5
1262	Biology of Lung Cancer. 2016 , 912-926.e6	0
1261	Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing. 2017 , 98, 26-37	23

1260	Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. 2017 , 7, 40488		36
1259	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. 2017 , 7,		16
1258	Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications. 2017 , 36, 3375-3383		12
1257	Divergence of cAMP signalling pathways mediating augmented nucleotide excision repair and pigment induction in melanocytes. 2017 , 26, 577-584		7
1256	Integrated genomic and molecular characterization of cervical cancer. <i>Nature</i> , 2017 , 543, 378-384	50.4	755
1255	A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. 2017 , 35, 39.e1-39.e7		25
1254	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017 , 541, 359-364	50.4	320
1253	The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. 2017 , 36, 3168-3177		61
1252	Systematic analysis of telomere length and somatic alterations in 31 cancer types. 2017 , 49, 349-357		277
1251	DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. 2017 , 23, 386-395		128
1250	3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. 2017 , 9, 4		117
1249	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. 2017 , 31, 181-193		350
1248	Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma. 2017 , 77, 1649-1661		6
1247	Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs. 2017 , 8, 14249		25
1246	Checkpoint inhibition: new treatment options in urologic cancer. 2017 , 72, 24-28		8
1245	Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. 2017 , 77, 817-822		88
1244	Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. 2017 , 77, 509-519		60
1243	Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. 2017 , 168, 460-472.e14		75

1242 Molecular Genetics of Neuroblastoma. **2017**, 83-125

1241	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. 2017 , 77, 1730-1740	16
1240	Molecular classification of gastric cancer. 2017 , 17, 293-301	47
1239	Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis. 2017 , 400, 305-323	17
1238	[Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma]. 2017 , 37, 55-60	1
1237	[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. 2017 , 37, 46-54	1
1236	Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. 2017 , 77, 2255-2265	121
1235	Targeting neoantigens to augment antitumour immunity. 2017 , 17, 209-222	449
1234	One thousand somatic SNVs per skin fibroblast cell set baseline of mosaic mutational load with patterns that suggest proliferative origin. 2017 , 27, 512-523	48
1233	Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. 2017 , 18, 303-310	10
1232	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. 2017 , 23, 3575-3584	54
1231	Assessment of tumor-infiltrating TCRV9V2 lymphocyte abundance by deconvolution of human cancers microarrays. 2017 , 6, e1284723	78
1230	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. 2017 , 13, 914	44
1229	CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations. 2017 , 77, 1918-1926	19
1228	[Current events in immunotherapy for upper aerodigestive tract cancer]. 2017 , 37, 79-89	7
1227	Germline mutations predisposing to diffuse large B-cell lymphoma. 2017 , 7, e532	15
1226	Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. 2017 , 35, 934-946	257
1225	Identification of coding and non-coding mutational hotspots in cancer genomes. 2017 , 18, 17	17

1224	Precision medicine driven by cancer systems biology. 2017 , 36, 91-108	30
1223	Non-coding genetic variation in cancer. 2017 , 1, 9-15	23
1222	Identification of Genomic Somatic Variants in Cancer: From Discovery to Actionability. 2017 , 78, 123-162	2
1221	B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers. 2017 , 7, 44089	22
1220	Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials. 2017 , 26, 415-426	4
1219	Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression. 2017 , 58, 1-11	16
1218	Functional germline variants in driver genes of breast cancer. 2017 , 28, 259-271	7
1217	Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex. 2017 , 18, 2135-2147	61
1216	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. 2017 , 92, 283-290	31
1215	Genomic complexity and targeted genes in anaplastic thyroid cancer cell lines. 2017 , 24, 209-220	13
1214	An integrated analysis of cancer genes in clear cell renal cell carcinoma. 2017 , 13, 715-725	5
1213	The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. 2017 , 8, 4565	78
1212	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. 2017 , 6, e1253654	87
1211	Prevention of DNA damage in human skin by topical sunscreens. 2017 , 33, 135-142	32
1210	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. 2017 , 23, 3859-3870	92
1209	Pediatric oncology enters an era of precision medicine. 2017 , 41, 194-200	32
1208	The evolving genomic landscape of urothelial carcinoma. 2017 , 14, 215-229	61
1207	High expression of PD-1 ligands is associated with mutational signature and APOBEC3 alterations. 2017 , 6, e1284719	42

1206	Restoration of the tumor-suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells. 2017 , 37, 594-600	24
1205	Discovery of Cancer Driver Long Noncoding RNAs across 1112 Tumour Genomes: New Candidates and Distinguishing Features. 2017 , 7, 41544	58
1204	Tissue-specific tumorigenesis: context matters. 2017 , 17, 239-253	160
1203	Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia. 2017 , 18, 23	3
1202	Identification of outcome-related driver mutations in cancer using conditional co-occurrence distributions. 2017 , 7, 43350	3
1201	TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. 2017 , 276, 165-177	86
1200	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. 2017 , 5, 319-329	9
1199	A population genetics perspective on the determinants of intra-tumor heterogeneity. 2017 , 1867, 109-126	29
1198	Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. 2017 , 7, 410-423	77
1197	is recurrently mutated in Middle Eastern colorectal cancer. 2018 , 67, 663-671	9
1196	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. 2017 , 54, 68-73	52
1195	Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation. 2017 , 36, 3789-3795	2
1194	Paracrine regulation of melanocyte genomic stability: a focus on nucleotide excision repair. 2017 , 30, 284-293	8
1193	Bladder cancer immunotherapy: swinging for the fences. 2017 , 13, 773-775	
1192	Integrated genomic analyses of de novo pathways underlying atypical meningiomas. 2017 , 8, 14433	95
1191	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. 2017 , 18, 255-262	260
1190	Molecular Biology, Genomics, Proteomics, and Mouse Models of Human Cancer. 2017 , 1-31	
1189	Cancer Genomics and Evolution. 2017 , 1-27	0

1188	Ultraviolet Radiation Carcinogenesis. 2017 , 1-8	1
1187	Chromosomal Instability in Gastric Cancer Biology. 2017 , 19, 412-420	27
1186	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. 2017 , 9, 34	1509
1185	Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia. 2017 , 51, 71-82.e3	20
1184	Variability in Chromatin Architecture and Associated DNA Repair at Genomic Positions Containing Somatic Mutations. 2017 , 77, 2822-2833	12
1183	A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. 2017 , 28, 996-1004	46
1182	Intrinsic Molecular Processes: Impact on Mutagenesis. 2017 , 3, 357-371	4
1181	Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade. 2017 , 13, 175-180	1
1180	Computational methods to dissect gene regulatory networks in cancer. 2017 , 2, 115-122	6
1179	Progression inference for somatic mutations in cancer. 2017 , 3, e00277	4
1178	Mutational signatures and mutable motifs in cancer genomes. 2018 , 19, 1085-1101	25
1177	Focus on cutaneous and uveal melanoma specificities. 2017 , 31, 724-743	55
1176	Exploring background mutational processes to decipher cancer genetic heterogeneity. 2017 , 45, W514-W522	41
1175	Heteroplasmic shifts in tumor mitochondrial genomes reveal tissue-specific signals of relaxed and positive selection. 2017 , 26, 2912-2922	28
1174	Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity. 2017 , 134, 201-230	16
1173	The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. 2017 , 1868, 221-230	16
1172	Molecular Events in the Natural History of Pancreatic Cancer. 2017 , 3, 336-346	45
1171	A three-caller pipeline for variant analysis of cancer whole-exome sequencing data. 2017 , 15, 2489-2494	10

1170	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. 2017 , 6, e1320626	47
1169	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. 2017 , 3, 1654-1662	146
1168	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. 2017 , 77, 3666-3671	47
1167	Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration. 2017 , 2, 103-114	29
1166	Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. 2017 , 23, 138-143	24
1165	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. 2017 , 7, 832-851	31
1164	Molecular Genetics of Endometrial Carcinoma. 2017 ,	1
1163	Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions. 2017 , 31, 1-12	10
1162	Next-Generation Sequencing. 2017 , 943, 119-148	31
1161	Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. 2017 , 109,	17
1160	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. 2017 , 7, 1018-1029	201
1159	Comprehensive Evaluation of Protein Coding Mononucleotide Microsatellites in Microsatellite-Unstable Colorectal Cancer. 2017 , 77, 4078-4088	16
1158	Character-Based Phylogeny Construction and Its Application to Tumor Evolution. 2017 , 3-13	1
1157	Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. 2017 , 41, 201-211	14
1156	New agents on the horizon in gastric cancer. 2017 , 28, 1767-1775	51
1155	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. 2017 , 22, 680-693	22
1154	Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. 2017 , 153, 536-549.e26	63
1153	Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. 2017 , 18, 451-469	20

1152	Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations. 2017 , 7, 973-983	65
1151	Somatic driver mutations in melanoma. 2017 , 123, 2104-2117	66
1150	Pancreatic Carcinogenesis. 2017 , 83-118	
1149	Early-onset Colorectal Cancer is Distinct From Traditional Colorectal Cancer. 2017 , 16, 293-299.e6	70
1148	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. 2017 , 82, 56-65	109
1147	Immunotherapy for Breast Cancer: What Are We Missing?. 2017 , 23, 2640-2646	112
1146	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. 2017 , 58, 22-33	51
1145	Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. 2017 , 72, 641-649	111
1144	A molecular portrait of microsatellite instability across multiple cancers. 2017 , 8, 15180	288
1143	Bioinformatics in translational drug discovery. 2017 , 37,	30
1142	Androgen receptor and miR-206 regulation in prostate cancer. 2017 , 8, 313-327	7
1141	Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patients. 2017 , 56, 730-749	14
1140	DDK Promotes Tumor Chemoresistance and Survival via Multiple Pathways. 2017 , 19, 439-450	14
1139	A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. 2017 , 14, 737-742	62
1138	Therapeutic T cell engineering. <i>Nature</i> , 2017 , 545, 423-431	50.4 420
1137	Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. 2017 , 8, 15290	109
1136	Digital Assays Part II: Digital Protein and Cell Assays. 2017 , 22, 387-405	21
1135	The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. 2017 , 102, 1617-1625	42

1134	Checkpoint Blockade Immunotherapy for Glioblastoma. 2017 , 261-300	2
1133	Genomic landscape of high-grade meningiomas. 2017 , 2,	78
1132	Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer. 2017 , 23, 2630-2639	15
1131	Network propagation: a universal amplifier of genetic associations. 2017 , 18, 551-562	285
1130	Elastic-Fluid Model for DNA Damage and Mutation from Nuclear Fluid Segregation Due to Cell Migration. 2017 , 112, 2271-2279	20
1129	Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma. 2017 , 242, 500-510	31
1128	Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis. 2017 , 216-217, 20-28	10
1127	ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. <i>Nature</i> , 2017 , 546, 671-675	47
1126	Wanted DEAD/H or Alive: Helicases Winding Up in Cancers. 2017 , 109,	45
1125	Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. 2017 , 9, 415-429	79
1124	Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel. 2017 , 7, 495	40
1123	Tackling non-muscle invasive bladder cancer in the clinic. 2017 , 17, 467-480	6
1122	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K. 2017 , 77, 2607-2619	123
1121	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. 2017 , 7, 586-595	347
1120	Chromatin marks shape mutation landscape at early stage of cancer progression. 2017 , 2, 9	7
1119	A Direct Test of Selection in Cell Populations Using the Diversity in Gene Expression within Tumors. 2017 , 34, 1730-1742	5
1118	Immunotherapy resistance: the answers lie ahead - not in front - of us. 2017 , 5, 10	12
1117	The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas. 2017 , 3, 584-589	10

1116	T-cell target antigens across major gynecologic cancers. 2017 , 145, 426-435	18
1115	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. 2017 , 995, 97-125	69
1114	Functional variomics and network perturbation: connecting genotype to phenotype in cancer. 2017 , 18, 395-410	60
1113	Personalized and Cancer Models to Guide Precision Medicine. 2017 , 7, 462-477	477
1112	Enhancing knowledge discovery from cancer genomics data with Galaxy. 2017 , 6, 1-13	6
1111	Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. 2017 , 39, e183-e186	11
1110	Biomarkers to predict prognosis and response to checkpoint inhibitors. 2017 , 22, 629-634	39
1109	Medulloblastoma: Molecular Classification-Based Personal Therapeutics. 2017 , 14, 265-273	47
1108	Computational approach for deriving cancer progression roadmaps from static sample data. 2017 , 45, e69	8
1107	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. 2017 , 2,	82
1106	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. 2017 , 7, 738	7
1105	Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor. 2017 , 103, 1340-1349	22
1104	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. 2017 , 9, 451-460	9
1103	A comprehensive analysis of cancer-driving mutations and genes in kidney cancer. 2017 , 13, 2151-2160	4
1102	Obstacles Posed by the Tumor Microenvironment to T-cell Activity: A Case for Synergistic Therapies. 2017 , 31, 311-325	326
1101	Integrated Molecular Characterization of Uterine Carcinosarcoma. 2017 , 31, 411-423	210
1100	Adenoid Cystic Carcinoma of the Breast. 2017 , 357-363	
1099	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. 2017 , 18, 2780-2794	247

1098	NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. 2017 , 11, 438-451	73
1097	Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. 2017 , 36, 4161-4170	51
1096	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies Inactivation Impairing Immunorecognition. 2017 , 23, 3203-3213	45
1095	Immunotherapy. 2017 ,	4
1094	Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. 2017 , 5, 376-384	63
1093	Identification of an atypical etiological head and neck squamous carcinoma subtype featuring the CpG island methylator phenotype. 2017 , 17, 223-236	44
1092	IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS. 2017 , 22, 473-484	5
1091	A critical discussion on diet, genomic mutations and repair mechanisms in colon carcinogenesis. 2017 , 265, 106-116	11
1090	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. 2017 , 389, 67-76	1171
1089	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition. 2017 , 23, 3203-3213	45
1088	Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. 2017 , 103, 44-51	56
1087	Modeling cancer rearrangement landscapes. 2017 , 1, 54-61	10
1086	The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. 2017 , 136, 129-148	69
1085	APOBEC3A/B-induced mutagenesis is responsible for 20% of heritable mutations in the TpCpW context. 2017 , 27, 175-184	19
1084	Building proteomic tool boxes to monitor MHC class I and class II peptides. 2017 , 17, 1600061	20
1083	Critical Issues in Head and Neck Oncology. 2017 ,	
1082	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. 2017 , 12, 75-102	19
1081	Integrated genomic characterization of oesophageal carcinoma. <i>Nature</i> , 2017 , 541, 169-175	50.4 965

1080	Using knowledge-driven genomic interactions for multi-omics data analysis: metadimensional models for predicting clinical outcomes in ovarian carcinoma. 2017 , 24, 577-587	35
1079	Cross-species analysis of the canine and human bladder cancer transcriptome and exome. 2017 , 56, 328-343	18
1078	Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. 2017 , 18, 248-262	1179
1077	Looking beyond drivers and passengers in cancer genome sequencing data. 2017 , 28, 938-945	22
1076	SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. 2017 , 49, 289-295	172
1075	pathTiME: Joint Inference of Mutually Exclusive Cancer Pathways and Their Progression Dynamics. 2017 , 24, 603-615	19
1074	Emerging biomarkers for PD-1 pathway cancer therapy. 2017 , 11, 53-67	9
1073	A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. 2017 , 18, 202-211	227
1072	Intratumor and Intertumor Heterogeneity in Melanoma. 2017 , 10, 956-975	124
1071	T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. 2017 , 5, 978-991	97
1070	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. 2017 , 8, 707	82
1069	Network-Based Coverage of Mutational Profiles Reveals Cancer Genes. 2017 , 5, 221-229.e4	24
1068	Nuclear topology modulates the mutational landscapes of cancer genomes. 2017 , 24, 1000-1006	22
1067	Genetic and Functional Drivers of Diffuse Large B'Cell Lymphoma. 2017 , 171, 481-494.e15	499
1066	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. 2017 , 8, 1197	46
1065	Genomics and advances towards precision medicine for head and neck squamous cell carcinoma. 2017 , 2, 310-319	10
1064	Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. 2017 , 32, 23-46	76
1063	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. 2017 , 171, 540-556.e25	961

1062	SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. 2017 , 49, 1613-1623	121
1061	Overexpressed somatic alleles are enriched in functional elements in Breast Cancer. 2017 , 7, 8287	3
1060	[Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models]. 2017 , 38, 160-168	4
1059	Emerging Opportunities for Target Discovery in Rare Cancers. 2017 , 24, 1075-1091	24
1058	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. 2017 , 280, 249-279	110
1057	[Report of the Working Group on Osseous, Joint and Soft Tissue Pathology : DGP conference on 22nd June 2017, Erlangen]. 2017 , 38, 233-237	
1056	Signatures of positive selection reveal a universal role of chromatin modifiers as cancer driver genes. 2017 , 7, 13124	7
1055	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 2017 , 17, 1055-1069	19
1054	Clonal Heterogeneity Influences the Fate of New Adaptive Mutations. 2017 , 21, 732-744	20
1053	Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy. 2017 , 36, 338-351	10
1052	Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. 2017 , 9,	184
1051	Universal Patterns of Selection in Cancer and Somatic Tissues. 2017 , 171, 1029-1041.e21	576
1050	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. 2017 , 8, 1050	75
1049	The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers. 2017 , 21, 997-999	7
1048	Antibody-Based Therapeutics in Oncology. 2017 , 521-585	
1047	Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain. 2017 , 171, 163-178.e19	203
1046	Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. 2017 , 60, 44-52	62
1045	Genomic characterization of tobacco/nut chewing HPV-negative early stage tongue tumors identify MMP10 as a candidate to predict metastases. 2017 , 73, 56-64	20

1044	Nucleotide Excision Repair: From Neurodegeneration to Cancer. 2017 , 1007, 17-39	15
1043	Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. 2017 , 28, 2458-2463	49
1042	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. 2017 , 11, 353-373	19
1041	NRAS-driven melanoma: A RAF can hide another. 2017 , 4, e1344758	1
1040	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. 2017 , 49, 1476-1486	255
1039	Low tumour cell content in a lung tumour bank: implications for molecular characterisation. 2017 , 49, 611-617	3
1038	Discovering potential driver genes through an integrated model of somatic mutation profiles and gene functional information. 2017 , 13, 2135-2144	14
1037	Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. 2017 , 13, 1997-2003	4
1036	Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. 2017 , 28, 2595-2605	139
1035	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. 2017 , 109,	40
1034	Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity. 2017 , 27, 1645-1657	68
1033	Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. 2017 , 6, 2347-2356	35
1032	Predictors of responses to immune checkpoint blockade in advanced melanoma. 2017 , 8, 592	122
1031	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. 2017 , 187, 2246-2258	66
1030	Analysis of somatic microsatellite indels identifies driver events in human tumors. 2017 , 35, 951-959	72
1029	Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. 2017 , 32,	13
1028	Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. 2017 , 102, e499-e501	19
1027	Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA. 2017 , 2, 25	5

1026	Precision Oncology: The Road Ahead. 2017 , 23, 874-898	71
1025	CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons. 2017 , 67, 1068-1079.e4	191
1024	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. 2017 , 8, 319	139
1023	APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. 2017 , 8, 465	60
1022	HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology. 2017 , 27, 1573-1588	52
1021	Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. 2017 , 243, 242-254	35
1020	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017 , 547, 311-317	50.4 472
1019	Contrasting Determinants of Mutation Rates in Germline and Soma. 2017 , 207, 255-267	14
1018	Mutational signatures efficiently identify different mutational processes underlying cancers with similar somatic mutation spectra. 2017 , 806, 27-30	2
1017	Clonality analysis of synchronous gastro-oesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing. 2017 , 243, 165-175	8
1016	Comparison of algorithms for the detection of cancer drivers at subgene resolution. 2017 , 14, 782-788	51
1015	Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma. 2017 , 67, 69-77	22
1014	Genomic approaches to accelerate cancer interception. 2017 , 18, e494-e502	27
1013	Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond. 2017 , 97, 81-113	8
1012	Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types. 2017 , 7, 6418	9
1011	Towards personalized tumor markers. 2017 , 1, 17	15
1010	Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas. 2017 , 108, 1888-1896	20
1009	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. 2017 , 2, e000200	25

1008 Immunonkologie bei Brustkrebs. **2017**, 50, 546-550

1007 The importance for immunoregulation for long-term cancer control. **2017**, 13, 1619-1632

8

1006 Identification of essential genes for cancer immunotherapy. *Nature*, **2017**, 548, 537-542

50.4 460

1005 *K-means and cluster models for cancer signatures. **2017**, 13, 7-31

14

1004 EGFR mutational status in lung adenocarcinoma: Staging implications or continuous evolution?. **2017**, 154, 1766-1767

1003 Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. **2017**, 12, 1696-1703

8

1002 Carcinogen susceptibility is regulated by genome architecture and predicts cancer mutagenesis. **2017**, 36, 2829-2843

47

1001 Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. **2017**, 9, 533-550

56

1000 Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. **2017**, 19, 64

71

999 The Immunology of Melanoma. **2017**, 37, 449-471

21

998 Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. **2017**, 32, 185-203.e13

896

997 AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. **2017**, 20, 1329-1341

119

996 Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. **2017**, 18, 51

56

995 NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma. **2017**, 7, 17064

34

994 Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas. **2017**, 2, 29

12

993 Myeloproliferative neoplasms: from origins to outcomes. **2017**, 130, 2475-2483

58

992 Integrating Clinical and Multiple Omics Data for Prognostic Assessment across Human Cancers. **2017**, 7, 16954

56

991 Detection of Somatic Mutations in Exome Sequencing of Tumor-only Samples. **2017**, 7, 15959

6

990	Advances in the Genetics and Biology of Pancreatic Cancer. 2017 , 23, 315-320	14
989	Mismatch repair prefers exons. 2017 , 49, 1673-1674	3
988	Personalised medicine for nonsmall cell lung cancer. 2017 , 26,	28
987	Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer. 2017 , 18, 100	32
986	Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. 2017 , 8, 1533	51
985	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. 2017 , 8, 1315	135
984	Bayesian inference of negative and positive selection in human cancers. 2017 , 49, 1785-1788	46
983	Reduced mutation rate in exons due to differential mismatch repair. 2017 , 49, 1684-1692	91
982	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. 2017 , 8, 1324	314
981	Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. 2017 , 8, 1323	38
980	The activated conformation of integrin β 5 is a novel multiple myeloma-specific target for CAR T cell therapy. 2017 , 23, 1436-1443	73
979	Fundamental Pathways in Breast Cancer 4: Signaling to Chromatin in Breast Development. 2017 , 27-37	
978	Neoantigens in the immuno-oncology space. 2017 , 13, 2209-2211	2
977	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. 2017 , 171, 950-965.e28	451
976	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. 2017 , 16, 272-294	3
975	Mutational Heterogeneity in and Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis. 2017 , 23, 5936-5947	19
974	A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay. 2017 , 8, 15943	30
973	Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. 2017 , 36, 6041-6048	8

972	Somatic mutations in ZFH4 gene are associated with poor overall survival of Chinese esophageal squamous cell carcinoma patients. 2017 , 7, 4951	20
971	Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers. 2017 , 14, 649-663	7
970	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. 2017 , 5, 685-694	24
969	Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. 2017 , 27, 1300-1311	50
968	Spectral clustering using Nyström approximation for the accurate identification of cancer molecular subtypes. 2017 , 7, 4896	2
967	Evolution of Local Mutation Rate and Its Determinants. 2017 , 34, 1100-1109	19
966	Recurrent and functional regulatory mutations in breast cancer. <i>Nature</i> , 2017 , 547, 55-60	50.4 192
965	Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1. 2017 , 9, 46	53
964	Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. 2017 , 49, 1274-1281	74
963	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. 2017 , 49, 1211-1218	430
962	Fast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut. 2017 , 18, 73	15
961	Revealing cancer subtypes with higher-order correlations applied to imaging and omics data. 2017 , 10, 20	7
960	CVE: an R package for interactive variant prioritisation in precision oncology. 2017 , 10, 37	7
959	The NF1 somatic mutational landscape in sporadic human cancers. 2017 , 11, 13	130
958	Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a. 2017 , 141, 1589-1599	13
957	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. 2017 , 19, 2878-2880	102
956	Immunotherapy of Prostate Cancer: Facts and Hopes. 2017 , 23, 6764-6770	108
955	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. 2017 , 7, 1116-1135	368

954	Integrative cancer genomics: models, algorithms and analysis. 2017 , 11, 392-406	1
953	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. 2017 , 18, 178-188.e4	1
952	The molecular basis of breast cancer pathological phenotypes. 2017 , 241, 375-391	62
951	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. 2017 , 1, 223-240	16
950	Genomic mechanisms of transformation from chronic obstructive pulmonary disease to lung cancer. 2017 , 42, 52-59	15
949	Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity. 2017 , 85, 51-57	21
948	Precision medicine in pediatric oncology: Lessons learned and next steps. 2017 , 64, e26288	51
947	Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. 2017 , 31, 1177-1186	5
946	Leveraging the immune system to treat advanced thyroid cancers. 2017 , 5, 469-481	39
945	Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy. 2017 , 68, 113-125	25
944	Developments in targeted therapy in melanoma. 2017 , 43, 581-593	28
943	The challenges of tumor genetic diversity. 2017 , 123, 917-927	41
942	Genomic complexity of multiple myeloma and its clinical implications. 2017 , 14, 100-113	267
941	Immunotherapy for the Treatment of Urothelial Carcinoma. 2017 , 197, 14-22	70
940	Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. 2017 , 23, 735-745	62
939	Role of epigenetics in lung cancer heterogeneity and clinical implication. 2017 , 64, 18-25	32
938	Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. 2017 , 64, 98-106	37
937	UV-Induced DNA Damage and Mutagenesis in Chromatin. 2017 , 93, 216-228	45

936	Landscape of Genomic Alterations in Pituitary Adenomas. 2017 , 23, 1841-1851	64
935	Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. 2017 , 28, 83-89	63
934	APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers. 2017 , 36, 1687-1697	34
933	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. 2017 , 80, 7-14	28
932	Personalized cancer vaccines: Targeting the cancer mutanome. 2017 , 35, 1094-1100	39
931	(Neuro)degenerated Mitochondria-ER contacts. 2017 , 483, 1096-1109	22
930	Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. 2017 , 23, 114-119	207
929	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. 2017 , 23, 3214-3222	28
928	Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. 2017 , 42, 13-19	37
927	Bupleurum chinense polysaccharide inhibit adhesion of human melanoma cells via blocking α integrin function. 2017 , 156, 244-252	7
926	Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. 2017 , 93, 245-258	6
925	Comprehensive characterization of cancer genes in hepatocellular carcinoma genomes. 2018 , 15, 1503-1510	10
924	Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. 2017 , 1, 33	17
923	Network-Based Identification of Adaptive Pathways in Evolved Ethanol-Tolerant Bacterial Populations. 2017 , 34, 2927-2943	9
922	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. 2017 ,	78
921	Clinical significance of BRAF mutation in circulating tumor DNA in Chinese patients with melanoma. 2018 , 15, 1839-1844	11
920	Genomic and Proteomic Resolution of Heterochromatin and Its Restriction of Alternate Fate Genes. 2017 , 68, 1023-1037.e15	99
919	Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1. 2017 , 8, 2249	11

918	A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data. 2017 , 18, 508	79
917	High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. 2017 , 7, e612	99
916	Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. 2017 , 45, 583-596	12
915	Depletion of somatic mutations in splicing-associated sequences in cancer genomes. 2017 , 18, 213	8
914	Performance comparison of NextSeq and Ion Proton platforms for molecular diagnosis of clinical oncology. 2017 , 103, 223-230	2
913	A method to reduce ancestry related germline false positives in tumor only somatic variant calling. 2017 , 10, 61	18
912	Whole genome sequencing of liver cancer for precision medicine. 2017 , 58, 551-558	
911	SWI/SNF-Komplex-assoziierte Tumordispositions-Syndrome. 2017 , 29, 296-305	2
910	Identification of cancer drug sensitivity biomarkers. 2017 ,	
909	Global unleashing of transcription elongation waves in response to genotoxic stress restricts somatic mutation rate. 2017 , 8, 2076	36
908	Transcriptional landscape of human cancers. 2017 , 8, 34534-34551	46
907	Erratum. 2017 , 92, 290-290	
906	. 2017 ,	4
905	How cancer immunotherapy works. 2017 ,	
904	Myeloproliferative neoplasms: from origins to outcomes. 2017 , 2017, 470-479	10
903	The Genomic Landscape of Cancers. 2017 , 69-86	9
902	MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. 2017 , 2017, 6501385	9
901	Recent Advances in the Neoadjuvant Treatment of Breast Cancer. 2017 , 20, 119-131	45

900	Non-coding cancer driver candidates identified with a sample- and position-specific model of the somatic mutation rate. 2017 , 6,	26
899	Cancer as a Paradigm for Translational and Clinical Biomedical Research. 2017 , 587-607	
898	Mathematical and Computational Modeling in Complex Biological Systems. 2017 , 2017, 5958321	44
897	Mutations in Cancer Cause Gain of Cysteine, Histidine, and Tryptophan at the Expense of a Net Loss of Arginine on the Proteome Level. 2017 , 7,	10
896	Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology. 2016 , 18,	32
895	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. 2017 , 18,	234
894	Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. 2017 , 18,	30
893	Pan-Cancer Mutational and Transcriptional Analysis of the Integrator Complex. 2017 , 18,	18
892	Mutational Signatures Are Critical for Proper Estimation of Purifying Selection Pressures in Cancer Somatic Mutation Data When Using the dN/dS Metric. 2017 , 8, 74	21
891	Computational Methods for Characterizing Cancer Mutational Heterogeneity. 2017 , 8, 83	16
890	Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. 2017 , 8, 555	52
889	Domesticating Cancer: An Evolutionary Strategy in the War on Cancer. 2017 , 7, 304	3
888	Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. 2017 , 2017, 5986129	33
887	Cancer Is to Embryology as Mutation Is to Genetics: Hypothesis of the Cancer as Embryological Phenomenon. 2017 , 2017, 3578090	25
886	MicroRNA-based molecular classification of papillary thyroid carcinoma. 2017 , 50, 1767-1777	55
885	The current status of immunobased therapies for metastatic renal-cell carcinoma. 2017 , 6, 83-93	8
884	Modeling Cancer Using CRISPR-Cas9 Technology. 2017 , 905-924	
883	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. 2017 , 2,	137

882	Bioinformatics and Drug Discovery. 2017 , 17, 1709-1726	72
881	Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis. 2017 , 12, e0176659	10
880	Comparative proteomic investigation of metastatic and non-metastatic osteosarcoma cells of human and canine origin. 2017 , 12, e0183930	17
879	MrTADFinder: A network modularity based approach to identify topologically associating domains in multiple resolutions. 2017 , 13, e1005647	28
878	Significant associations between driver gene mutations and DNA methylation alterations across many cancer types. 2017 , 13, e1005840	21
877	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. 2017 , 17, 618	25
876	Identification of trunk mutations in gastric carcinoma: a case study. 2017 , 10, 49	4
875	Automated identification of reference genes based on RNA-seq data. 2017 , 16, 65	13
874	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. 2017 , 10, 146	57
873	Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. 2017 , 18, 141	20
872	Differential analysis between somatic mutation and germline variation profiles reveals cancer-related genes. 2017 , 9, 79	11
871	Predicting cancer type from tumour DNA signatures. 2017 , 9, 104	25
870	Using single-cell multiple omics approaches to resolve tumor heterogeneity. 2017 , 6, 46	50
869	Immunotherapie thorakaler Tumoren. 2017 , 20, 21-27	
868	Beyond Perfect Phylogeny. 2017 ,	32
867	QuaDMutEx: quadratic driver mutation explorer. 2017 , 18, 458	3
866	Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer. 2017 , 18, 472	3
865	Incorporating biological prior knowledge for Bayesian learning via maximal knowledge-driven information priors. 2017 , 18, 552	23

864	Nivolumab Therapy for Synchronous -Positive Lung Cancer and Gastric Cancer. 2017 , 10, 361-367	3
863	Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. 2017 , 8, 71234-71248	18
862	Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. 2017 , 8, 40683-40692	53
861	Characterization of potential driver mutations involved in human breast cancer by computational approaches. 2017 , 8, 50252-50272	28
860	Comparative analysis of primary relapse/refractory DLBCL identifies shifts in mutation spectrum. 2017 , 8, 99237-99244	14
859	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. 2017 , 1, 471-486	3
858	Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. 2017 , 8, 69888-69905	14
857	Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. 2017 , 1, 123-132	23
856	The landscape of genetics and biomarkers in bladder cancer. 2017 , 6, 1027-1030	4
855	Mutation-profile-based methods for understanding selection forces in cancer somatic mutations: a comparative analysis. 2017 , 8, 58835-58846	3
854	Perturbations in the Replication Program Contribute to Genomic Instability in Cancer. 2017 , 18,	18
853	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. 2017 , 11, 1175-1182	10
852	Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities. 2017 , 7, 1088-1099	76
851	Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. 2017 , 8, 513-522	20
850	Validation of a Circulating Tumor-Derived DNA Blood Test for Detection of Methylated BCAT1 and IKZF1 DNA. 2017 , 2, 165-175	5
849	Hirnmetastasen beim malignen Melanom. 2017 , 38, 196-201	
848	Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. 2017 , 35, 984-993	37
847	Hypermutation and microsatellite instability in gastrointestinal cancers. 2017 , 8, 112103-112115	46

846	Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. 2017 , 35, 2018-2027	61
845	Identification and characterization of HPV-independent cervical cancers. 2017 , 8, 13375-13386	54
844	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. 2017 , 2017,	28
843	Bending the Curve of Advanced Urothelial Carcinoma. 2017 , 13, 319-320	
842	Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. 2017 , 37, 106-115	5
841	The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. 2017 , 8, 16421-16429	43
840	Identification and analysis of mutational hotspots in oncogenes and tumour suppressors. 2017 , 8, 21290-21304	6
839	Identification of novel diagnostic biomarkers for thyroid carcinoma. 2017 , 8, 111551-111566	5
838	Biologics in gastrointestinal and pancreatic neuroendocrine tumors. 2017 , 8, 457-465	8
837	Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next?. 2017 , 9, E519-E521	3
836	Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. 2017 , 6, 1081-1089	20
835	Current markers and their value in the era of immuno-oncology. 2017 , 6, 1111-1116	5
834	Precision Medicine and Challenges in Research and Clinical Implementation. 2017 , 717-732	1
833	experimental models of mesothelioma revisited. 2017 , 6, 248-258	11
832	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.. 2017 , 1, 1-15	31
831	Advances in the Treatment of Pediatric Bone Sarcomas. 2017 , 37, 725-735	20
830	Recon3D enables a three-dimensional view of gene variation in human metabolism. 2018 , 36, 272-281	283
829	First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright. 2018 , 73, 653-655	3

828	Are liquid biopsies a surrogate for tissue EGFR testing?. 2018 , 29, i38-i46	42
827	Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach. 2018 , 8, 3284	9
826	Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection. 2018 , 18, e1700284	18
825	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. 2018 , 8, 730-749	235
824	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. 2018 , 8, 4159	51
823	Whole genome sequencing analysis for cancer genomics and precision medicine. 2018 , 109, 513-522	129
822	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. <i>Nature</i> , 2018 , 555, 371-376	50.4 380
821	Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. 2018 , 4, eaa05508	37
820	The molecular landscape of head and neck cancer. 2018 , 18, 269-282	524
819	The possibility of cancer immune editing in gliomas. A critical review. 2018 , 7, e1445458	25
818	MOAT: efficient detection of highly mutated regions with the Mutations Overburdening Annotations Tool. 2018 , 34, 1031-1033	7
817	A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy. 2018 , 1864, 2315-2328	12
816	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. 2018 , 65, 54-64	40
815	Aggressive natural killer-cell leukemia ´mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. 2018 , 9, 1567	72
814	Treatment and outcome of adult-onset neuroblastoma. 2018 , 143, 1249-1258	15
813	Bridging Information on Drugs, Targets, and Diseases. 2018 , 195-205	
812	Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. 2018 , 131, 2283-2296	59
811	Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. 2018 , 26, 1414-1422	67

810	Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. 2018 , 9, 1591	40
809	Epigenetic landscape influences the liver cancer genome architecture. 2018 , 9, 1643	27
808	Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases. 2018 , 11,	5
807	Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers. 2018 , 143, 1696-1705	33
806	The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma. 2018 , 13, 437-446	21
805	Sarcoma-The standard-bearer in cancer discovery. 2018 , 126, 1-5	19
804	Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK. 2018 , 29-49	
803	Comprehensive Characterization of Cancer Driver Genes and Mutations. 2018 , 173, 371-385.e18	854
802	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. 2018 , 173, 291-304.e6	888
801	Oncogenic Signaling Pathways in The Cancer Genome Atlas. 2018 , 173, 321-337.e10	1124
800	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. 2018 , 23, 282-296.e4	188
799	A novel unsupervised learning model for detecting driver genes from pan-cancer data through matrix tri-factorization framework with pairwise similarities constraints. 2018 , 296, 64-73	20
798	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. 2018 , 23, 172-180.e3	66
797	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. 2018 , 23, 213-226.e3	56
796	Proteogenomics of Malignant Melanoma Cell Lines: The Effect of Stringency of Exome Data Filtering on Variant Peptide Identification in Shotgun Proteomics. 2018 , 17, 1801-1811	10
795	[Therapeutic advances in the management of biliary tract carcinoma]. 2018 , 47, 419-422	1
794	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. 2018 , 23, 255-269.e4	112
793	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. 2018 , 23, 270-281.e3	121

792	Anti-colon-cancer effects of polysaccharides: A mini-review of the mechanisms. 2018 , 114, 1127-1133	44
791	Disruption of in Head and Neck Cancer Promotes Favorable Chemotherapeutic Responses Linked to Hypomethylation. 2018 , 17, 1585-1594	30
790	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. 2018 , 33, 843-852.e4	525
789	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. 2018 , 173, 611-623.e17	228
788	[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. 2018 , 105, 263-274	10
787	Genomic Feature Selection by Coverage Design Optimization. 2018 , 45, 2658-2676	1
786	Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. 2018 , 8, 3161	23
785	Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. 2018 , 37, 2444-2455	20
784	Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. 2018 , 68, 959-969	149
783	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. 2018 , 52, 228-240	162
782	Recent developments in the treatment of advanced bladder cancer. 2018 , 36, 109-114	25
781	Role of artificial intelligence in the care of patients with nonsmall cell lung cancer. 2018 , 48, e12901	38
780	The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment. 2018 , 28, 43-50	11
779	[The biological rationale for immunotherapy in cancer]. 2018 , 35, 206-222	4
778	TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. <i>Nature</i> , 2018 , 554, 538-543	50.4 849
777	Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. 2018 , 3, 1	38
776	Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. 2018 , 118, 139-147	8
775	Bioimpedimetric analysis in conjunction with growth dynamics to differentiate aggressiveness of cancer cells. 2018 , 8, 783	18

774	Comprehensive Analysis of DNA Methylation and Gene Expression Datasets Identified MMP9 and TWIST1 as Important Pathogenic Genes of Lung Adenocarcinoma. 2018 , 37, 336-346	4
773	Neuroendocrine Gene Transcripts: The Role of Molecular Biomarkers in Diagnosis and Management. 2018 , 235-249	
772	Cancer genetics meets biomolecular mechanism-bridging an age-old gulf. 2018 , 592, 463-474	6
771	The value of cell-free DNA for molecular pathology. 2018 , 244, 616-627	62
770	Pathologic Evaluation of Triple-Negative Breast Cancer. 2018 , 1-22	2
769	Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. 2018 , 9, 216	87
768	A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. 2018 , 29, 938-944	43
767	Immune checkpoint inhibitors for metastatic bladder cancer. 2018 , 64, 11-20	57
766	The Integrated Genomic Landscape of Thymic Epithelial Tumors. 2018 , 33, 244-258.e10	150
765	Orchid: a novel management, annotation and machine learning framework for analyzing cancer mutations. 2018 , 34, 936-942	9
764	Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. 2018 , 14, 1023-1034	1
763	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. 2018 , 33, 202-216.e6	75
762	Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors. 2018 , 24, 1691-1704	33
761	ConsensusDriver Improves upon Individual Algorithms for Predicting Driver Alterations in Different Cancer Types and Individual Patients. 2018 , 78, 290-301	14
760	Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities. 2018 , 244, 638-649	21
759	Role of immunotherapy in bladder cancer: past, present and future. 2018 , 81, 629-645	26
758	Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond. 2018 , 24, 20-30	14
757	Identification of differential protein-coding gene expressions in early phase lung adenocarcinoma. 2018 , 9, 234-240	3

756	Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. 2018 , 37, 1354-1368	57
755	"Future-Proofing" Blood Processing for Measurement of Circulating miRNAs in Samples from Biobanks and Prospective Clinical Trials. 2018 , 27, 208-218	16
754	Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response. 2018 , 27, 156-166	21
753	Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. 2018 , 33, 137-150.e5	113
752	Interactome INSIDER: a structural interactome browser for genomic studies. 2018 , 15, 107-114	78
751	SWI/SNF (BAF) Complexes: Guardians of the Epigenome. 2018 , 2, 413-427	18
750	How many melanomas might be prevented if more people applied sunscreen regularly?. 2018 , 178, 140-147	18
749	New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome. 2018 , 78, 15-29	81
748	PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies. 2018 , 321-331	
747	Immune Checkpoint Inhibition in Lung Cancer. 2018 , 333-344	
746	PD-L1 and Other Immunological Diagnosis Tools. 2018 , 371-385	2
745	Immunotherapy for Prostate Cancer: An Evolving Landscape. 2018 , 593-606	2
744	Atezolizumab for platinum-treated metastatic urothelial carcinoma. 2018 , 391, 716-718	9
743	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Targeting the Right Antigens in the Right Patients. 2018 , 10,	5
742	Identifying pathways affected by cancer mutations. 2018 , 110, 318-328	4
741	Whole-exome sequencing demonstrates recurrent somatic copy number alterations and sporadic mutations in specialized stromal tumors of the prostate. 2018 , 76, 9-16	3
740	Precision Molecular Pathology of Bladder Cancer. 2018 ,	
739	Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response. 2018 , 181-194	

738	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. 2018 , 137, 269-278	23
737	Mechanisms of resistance to immune checkpoint inhibitors. 2018 , 118, 9-16	576
736	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. 2018 , 33, 125-136.e3	338
735	Hitting the Target: How T Cells Detect and Eliminate Tumors. 2018 , 200, 392-399	37
734	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. 2018 , 85-101	
733	Integrative genomic and transcriptomic analysis of leiomyosarcoma. 2018 , 9, 144	115
732	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. 2018 , 20, 472-483	31
731	Single cell patterning for high throughput sub-cellular toxicity assay. 2018 , 1007, 26-32	12
730	Integration of radiation and immunotherapy in breast cancer - Treatment implications. 2018 , 38, 66-74	26
729	Comprehensive Genomic Characterization of RNA-Binding Proteins across Human Cancers. 2018 , 22, 286-298	101
728	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. 2018 , 359, 801-806	562
727	Immunotherapy for Other Malignancies. 2018 , 125-142	
726	A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. 2018 , 52, 158-165	4
725	Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. 2018 , 7, e1356144	77
724	Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. 2018 , 9, 1746	95
723	Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. 2018 , 16, 94	73
722	Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment. 2018 , 12, 20	8
721	A site specific model and analysis of the neutral somatic mutation rate in whole-genome cancer data. 2018 , 19, 147	6

720	Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies. 2018 , 41, 266-271	15
719	Treatment resistance in urothelial carcinoma: an evolutionary perspective. 2018 , 15, 495-509	26
718	Genetics of metastasis: melanoma and other cancers. 2018 , 35, 379-391	33
717	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. 2018 , 24, 679-690	659
716	Clinical trial methodology in rare gynecologic tumor research: Strategies for success. 2018 , 149, 605-611	4
715	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. 2018 , 9, 1725	72
714	Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies. 2018 , 17, 1416-1429	29
713	Shedding light on the molecular determinants of response to anti-PD-1 therapy. 2015 , 4, 816-9	17
712	Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. 2015 , 19, 359-65	9
711	Androgen receptor facilitates the recruitment of macrophages in tumor microenvironment to promote upper urinary tract urothelial cell carcinoma progression. 2016 , 6, 1922-1934	
710	Annotating gene sets by mining large literature collections with protein networks. 2018 , 23, 602-613	6
709	Genomics of adult and pediatric solid tumors. 2018 , 8, 1356-1386	12
708	From genome to phenome: Predicting multiple cancer phenotypes based on somatic genomic alterations via the genomic impact transformer. 2020 , 25, 79-90	5
707	Heterogeneous genomic aberrations in esophageal squamous cell carcinoma: a review. 2020 , 12, 1553-1568	4
706	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. 2020 , 12, 5416-5432	4
705	[Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer]. 2020 , 38, 489-494	
704	Frequent Subgraph Mining of Functional Interaction Patterns Across Multiple Cancers. 2021 , 26, 261-272	
703	Inhibition of P53-mediated cell cycle control as the determinant in dedifferentiated liposarcomas development. 2021 , 11, 3271-3284	

702	Epigenetics and precision medicine in bone and soft tissue sarcomas. 2022 , 147-191	
701	An Integrative Pan-Cancer Analysis of PBK in Human Tumors. 2021 , 8, 755911	0
700	Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. 2021 , 12, 6946	1
699	DCMP: database of cancer mutant protein domains. 2021 , 2021,	
698	SECEDO: SNV-based subclone detection using ultra-low coverage single-cell DNA sequencing.	0
697	Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives. 2021 , 23, 428-435	
696	The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors. 2021 , 12, e00424	
695	Mutational landscape of high-grade B-cell lymphoma with -, and/or rearrangements characterized by whole-exome sequencing. 2021 ,	0
694	Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer. 2021 , 2021, 4251763	0
693	Statins mediate anti- and pro-tumourigenic functions in lung adenocarcinoma development by remodelling the tumour microenvironment. 2021 ,	4
692	Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. 2021 ,	2
691	Cancer Microbiology. 2021 ,	0
690	APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis.. 2021 , 2, 1338-1356	4
689	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma. 2021 , 13,	1
688	Melanoma Targeted Therapies beyond -Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. 2021 , 13,	2
687	Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma. 2021 , 8, 755657	0
686	Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy. 2021 ,	0
685	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. 2021 , 10,	4

684	Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia adenocarcinoma. 2021 , 12, 6489	3
683	Liquid biopsies in pediatric oncology: opportunities and obstacles. 2021 , 34,	0
682	Utilizing patient information to identify subtype heterogeneity of cancer driver genes. 2021 , 9622802211055854	
681	Therapeutic vaccines for breast cancer: Has the time finally come?. 2021 ,	5
680	Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants.. 2021 , 11, 752579	0
679	Genome Instability in Multiple Myeloma: Facts and Factors. 2021 , 13,	0
678	The ongoing mystery of renal cell cancer. 2021 , 2, 100445	
677	Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors. 2021 , 5,	3
676	Gattaca: Base pair resolution mutation tracking for somatic evolution studies using agent-based models.	
675	Cell Painting predicts impact of lung cancer variants.	0
674	Machine learning for prediction of immunotherapy efficacy in non- small cell lung cancer from simple clinical and biological data.	
673	Magenkarzinom: Neue molekulare Konzepte.	2
672	Comprehensive evaluation of computational methods for predicting cancer driver genes.. 2022 ,	1
671	Eye malignant melanoma ¶the correlation of clinical evolution with biological and immunological parameters. 2021 , 4, 23	
670	Next Generation Sequencing Reveals Pathogenic and Actionable Genetic Alterations of Soft Tissue Sarcoma in Chinese Patients: A Single Center Experience.. 2021 , 20, 15330338211068964	0
669	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. 2021 , 1342, 273-295	1
668	A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.. 2022 , 15, 1	0
667	Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma.. 2022 , 21, 1	3

666	Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.. 2022,	0
665	Biased expression of mutant alleles in cancer-related genes in esophageal squamous cell carcinoma.. 2022, 1	0
664	EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.. 2021,	0
663	Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.. 2022, 22, 46	1
662	When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.. 2022,	2
661	Biomarkers for predicting the efficacy of immune checkpoint inhibitors.. 2022, 13, 481-495	1
660	Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.. 2021,	7
659	Basics of immunotherapy for epithelial ovarian cancer. 2021, 102283	
658	Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms.. 2021 , 7, 100364	2
657	Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis.. 2021, 16, 101311	1
656	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.. 2021, 7, 100308	2
655	Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential. 2022, 4, 100018	
654	Immunotherapy of Gastric Cancer: Focus on Perioperative Strategies. 2021,	
653	Immunotherapy for Neuro-oncology.. 2021, 1342, 233-258	1
652	[CAR-T cells immunotherapy in multiple myeloma: Present and future].. 2021, 108, S65-S72	0
651	Tumour genotypes account for survival differences in right- and left-sided colon cancers.. 2022,	3
650	Cost-Efficiency Optimization Serves as a Conserved Mechanism that Promotes Osteosarcoma in Mammals.. 2022,	0
649	MHCroBERTa: pan-specific peptide-MHC class I binding prediction through transfer learning with label-agnostic protein sequences.. 2022,	

648 Regional Mutational Signature Activities in Cancer Genomes.

647 NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.. **2022**,

1

646 Integrative Genomic Analyses of 1,145 Patient Samples Reveal New Biomarkers in Esophageal Squamous Cell Carcinoma.. **2021**, 8, 792779

0

645 MutSigCVsyn: Identification of Thirty Synonymous Cancer Drivers.

644 Comparative assessment of genes driving cancer and somatic evolution in non-cancer tissues: an update of the Network of Cancer Genes (NCG) resource.. **2022**, 23, 35

0

643 VISTA, PDL-L1, and -A Review of New and Old Markers in the Prognosis of Melanoma.. **2022**, 58,

0

642 Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma.. **2022**, 14,

0

641 Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.. **2022**, 23,

1

640 The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.. **2021**, 11, 704999

0

639 Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer.. **2022**, 10,

3

638 An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.. **2021**,

4

637 Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.

636 NestedBD: Bayesian Inference of Phylogenetic Trees From Single-Cell DNA Copy Number Profile Data Under a Birth-Death Model.

0

635 A network-based method for detecting cancer driver gene in transcriptional regulatory networks using the structure analysis of weighted regulatory interactions.. **2022**, 17,

634 Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma.

633 Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions.. **2022**, 13, 178

0

632 Somatic and germline genomic alterations in very young women with breast cancer.. **2022**,

2

631 The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma.. **2021**, 11, 811434

0

630	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.. 2021 , 12, 798474	1
629	An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. 2022 , 2, 10-27	0
628	Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.. 2021 , 12, 798451	0
627	Updated fraction of cancer attributable to lifestyle and environmental factors in Denmark in 2018.. 2022 , 12, 549	0
626	Multi-omic data helps improve prediction of personalised tumor suppressors and oncogenes.	
625	Activation of the Integrated Stress Response overcomes multidrug resistance in FBXW7-deficient cells.	0
624	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance.. 2022 , 11,	1
623	KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.. 2022 , 17, e0251286	
622	Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer.. 2022 , 17, e0259992	0
621	Novel ratio-metric features enable the identification of new driver genes across cancer types.. 2022 , 12, 5	0
620	Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of Tumorigenesis.. 2022 , 14,	0
619	Massively parallel phenotyping of coding variants in cancer with Perturb-seq.. 2022 ,	6
618	Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice.. 2022 , 24, 13	2
617	Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.. 2022 ,	1
616	Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria.. 2022 ,	8
615	Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.. 2022 , 14,	1
614	GNIFdb: a neoantigen intrinsic feature database for glioma.. 2022 , 2022,	0
613	Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer.. 2022 , JCO2102864	

612	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.. 2022 , 13, 604	0
611	Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS).. 2022 , 12, 1701	1
610	Mechanisms of immune activation and regulation: lessons from melanoma.. 2022 ,	11
609	Machine learning for multi-omics data integration in cancer.. 2022 , 25, 103798	6
608	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.. 2021 ,	0
607	Transcription Factor-Centric Approach to Identify Non-Recurring Putative Regulatory Drivers in Cancer.	
606	Therapeutic Targeting of DNA Damage Response in Cancer.. 2022 , 23,	1
605	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. 2021 ,	3
604	Machine learning methods for prediction of cancer driver genes: a survey paper.. 2022 ,	1
603	Identification of a Five-Gene Panel to Assess Prognosis for Gastric Cancer.. 2022 , 2022, 5593619	0
602	SuperDendrix algorithm integrates genetic dependencies and genomic alterations across pathways and cancer types.. 2022 , 2, 100099-100099	0
601	Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA.. <i>Nature</i> , 2022 ,	50.4 5
600	Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.. 2021 , 20, 168	1
599	Anticancer drug resistance: An update and perspective.. 2021 , 100796	17
598	Cancer gene mutation frequencies for the U.S. population. 2021 , 12, 5961	15
597	Pan-Genomic Sequencing Reveals Actionable Deletions and Kataegis in Anaplastic Thyroid Carcinoma.. 2021 , 13,	2
596	CDKN1A/p21, RB1, ARID1A, FLG, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies. 2021 , 11, 5452-5471	2
595	Branching clonal evolution patterns predominate mutational landscape in multiple myeloma. 2021 , 11, 5659-5679	1

594	Multi-omic Approaches to Improve Cancer Diagnosis, Prognosis, and Therapeutics. 2022 , 411-433	
593	Why Precision Oncology Is Not Very Precise (and Why This Should Not Surprise Us). 2022 , 3-21	1
592	Development of RNA-Based Medicine for Colorectal Cancer: Current Scenario. 2022 , 339-360	
591	EPIMUTESTR: a nearest neighbor machine learning approach to predict cancer driver genes from the evolutionary action of coding variants.. 2022 ,	1
590	Network Approaches for Precision Oncology.. 2022 , 1361, 199-213	
589	Exploring the Peptide Potential of Genomes.. 2022 , 2405, 63-82	0
588	The role of DNA mismatch repair in immunotherapy of human cancer.. 2022 , 18, 2821-2832	0
587	Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.. 2022 , 10,	2
586	Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis.. 2022 , 13, 898	2
585	Examining clustered somatic mutations with SigProfilerClusters.	0
584	High-resolution lung adenocarcinoma expression subtypes identify tumors with dependencies on MET, CDK4, CDK6, and PD-L1.	
583	Is it time to reassess variant annotation?. 2022 ,	0
582	Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.. 2022 ,	2
581	Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.. 2022 , 14, eaax7706	1
580	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.. 2022 , 3, 100500	2
579	Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives.. 2022 , 14, 78-106	
578	Whole Exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.	
577	Systematic illumination of druggable genes in cancer genomes.. 2022 , 38, 110400	0

576	Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development.. 2022 , 10, 815596	1
575	Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?. 2022 , 23,	0
574	Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.. 2022 , 10,	1
573	DGMP: Identifying Cancer Driver Genes by Jointing DGCN and MLP from Multi-Omics Genomic Data.	0
572	Current Trends in Computational chemistry for Breast Cancer.. 2022 , 19,	
571	Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.. 2022 , 12, 788113	1
570	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.. 2022 , 23,	2
569	Genome Editing Applications in Cancer T Cell Therapy. 2022 , 213-229	
568	Cell Painting predicts impact of lung cancer variants.. 2022 , mbcE21110538	1
567	In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes.. 2022 , 2, e377	0
566	Computed Tomography Imaging-Based Radiogenomics Analysis Reveals Hypoxia Patterns and Immunological Characteristics in Ovarian Cancer.. 2022 , 13, 868067	4
565	Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy.. 2022 , 136, 383-404	1
564	Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.. 2022 , 23, 609	0
563	DNA repair phenotype and cancer risk: a systematic review and meta-analysis of 55 case-control studies.. 2022 , 12, 3405	1
562	Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.. 2022 ,	1
561	A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer.	
560	Gattaca: Base pair resolution mutation tracking for somatic evolution studies using agent-based models.. 2022 ,	0
559	Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Oropharynx and Nasopharynx.. 2022 , 1	3

558	Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics.. 2022 , 14,	0
557	Integrating whole genome sequencing, methylation, gene expression, topological associated domain information in regulatory mutation prediction: A study of follicular lymphoma.. 2022 , 20, 1726-1742	
556	Analysis of Genetic Alterations in Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma With Whole-Exome Sequencing.. 2022 , 12, 817635	0
555	Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer.. 2022 , 29, 1902-1918	1
554	Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.. 2022 , 13, 831146	1
553	HWVoteRank: A Network-Based Voting Approach for Identifying Coding and Non-Coding Cancer Drivers. 2022 , 10, 801	1
552	Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?-A Comprehensive Review.. 2022 , 11,	1
551	Mutation-Derived Long Noncoding RNA Signature Predicts Survival in Lung Adenocarcinoma.. 2022 , 12, 780631	1
550	The Expression Pattern of Ferroptosis-Related Genes in Colon Adenocarcinoma: Highly Correlated to Tumor Microenvironment Characteristics.. 2022 , 13, 837941	
549	An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases.. 2022 , 13, 842555	0
548	The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. 2022 ,	1
547	Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations.. 2022 ,	0
546	All is not lost: learning from 9p21 loss in cancer.. 2022 ,	0
545	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. 2022 , JCO2102767	7
544	Genome-wide analysis of somatic noncoding mutation patterns in cancer.. 2022 , 376, eabg5601	2
543	Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma.. 2022 , 18, 101367	1
542	Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.. 2022 , 14,	1
541	Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesions.. 2022 , 166, 178-188	0

540	Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma.. 2022,	
539	Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma.. 2022,	3
538	Driver Gene Detection through Bayesian Network Integration of Mutation and Expression Profiles.. 2022,	
537	Bayesian networks elucidate complex genomic landscapes in cancer.. 2022, 5, 306	1
536	OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study.. 2022, 10,	1
535	RB1 loss triggers dependence on ESRRG in retinoblastoma.	
534	Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors.. 2021, 118,	0
533	Correlation-based and feature-driven mutation signature analyses to identify genetic features associated with DNA mutagenic processes in cancer genomes.. 2021, 19, e40	0
532	Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis.. 2021, 14,	2
531	Molecular-based precision oncology clinical decision making augmented by artificial intelligence. 2021,	0
530	Computational analysis of cancer genome sequencing data. 2021,	2
529	Identification of mA Regulator-Associated Methylation Modification Clusters and Immune Profiles in Melanoma.. 2021, 9, 761134	0
528	Genomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?. 2021, 14,	1
527	DNA methylation variation along the cancer epigenome and the identification of novel epigenetic driver events. 2021,	1
526	DGAT-onco: A differential analysis method to detect oncogenes by integrating functional information of mutations. 2021,	
525	Molecular Characterization of Metanephric Adenoma, Epithelial Wilms Tumor, and Overlap Lesions: An Integrated Whole-exome and Transcriptome Sequencing Analysis.. 2022, 30, 257-263	0
524	Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data.. 2021, 13,	2
523	Mitochondrial Dysfunction is a Driver for SP-2509 Drug Resistance in Ewing Sarcoma.	1

522	Somatic mutations and CRISPR/Cas9 library screening integrated analysis identifies cervical cancer drug-resistant pathways.. 2021 , 11, e632	0
521	Novel Biomarkers and Druggable Targets in Advanced Melanoma.. 2021 , 14,	0
520	A full-proteome, interaction-specific characterization of mutational hotspots across human cancers.. 2021 ,	0
519	Genetic Subgroups Inform on Pathobiology in Adult and Pediatric Burkitt Lymphoma.	0
518	Can Systems Biology Advance Clinical Precision Oncology?. 2021 , 13,	1
517	A computational approach for the discovery of significant cancer genes by weighted mutation and asymmetric spreading strength in networks. 2021 , 11, 23551	
516	Attribution of Cancer Origins to Endogenous, Exogenous, and Preventable Mutational Processes.. 2022 , 39,	1
515	Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.. 2022 , 82, 1589-1602	0
514	Single-hit inactivation drove tumor suppressor genes out of the X chromosome during evolution.. 2022 ,	
513	Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.. 2022 , 9, 777775	0
512	m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma.. 2022 , 13, 864549	1
511	Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8 T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma.. 2022 , 15, 4209-4220	0
510	Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers.. 2022 , 14,	0
509	KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis.. 2022 , 13, 354	0
508	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.. 2022 , 41, 148	1
507	Effects of Multi-Omics Characteristics on Identification of Driver Genes Using Machine Learning Algorithms. 2022 , 13, 716	0
506	A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population.. 2022 , 13, 2052	1
505	Gene Mutations Associated With Clinical Characteristics in the Tumors of Patients With Breast Cancer.. 2022 , 12, 778511	0

- 504 Single-Cell Transcriptome Analysis Reveals Inter-Tumor Heterogeneity in Bilateral Papillary Thyroid Carcinoma.. **2022**, 13, 840811 0
- 503 Editorial overview: Vaccines: Reinvigorating therapeutic cancer vaccines.. **2022**, 76, 102176 1
- 502 Data_Sheet_1.PDF. **2019**,
- 501 Data_Sheet_1.zip. **2018**,
- 500 Presentation_1.pdf. **2018**,
- 499 Table_1.XLSX. **2020**,
- 498 Table_2.XLSX. **2020**,
- 497 Table_3.XLSX. **2020**,
- 496 Table_4.XLSX. **2020**,
- 495 Table_5.XLSX. **2020**,
- 494 Image_1.TIFF. **2019**,
- 493 Image_2.TIFF. **2019**,
- 492 Table_1.XLSX. **2019**,
- 491 Table_2.XLSX. **2019**,
- 490 Presentation_1.PDF. **2018**,
- 489 Table_1.XLSX. **2018**,
- 488 Table_2.XLSX. **2018**,
- 487 Table_3.XLSX. **2018**,

486 Table_4.XLSX. 2018,

485 Table_5.XLSX. 2018,

484 Table_6.XLSX. 2018,

483 Image_1.tif. 2020,

482 Image_2.tif. 2020,

481 Image_3.tif. 2020,

480 Table_1.XLSX. 2020,

479 Table_2.XLSX. 2020,

478 Table_3.XLSX. 2020,

477 Data_Sheet_1.PDF. 2019,

476 Data_Sheet_2.xlsx. 2019,

475 Data_Sheet_1.docx. 2021,

474 Table_2.XLS. 2021,

473 DataSheet_1.zip. 2019,

472 Image_1.tif. 2019,

471 Image_10.png. 2019,

470 Image_11.tif. 2019,

469 Image_12.tif. 2019,

468 Image_2.png. 2019,

467 Image_3.tif. 2019,

466 Image_4.tif. 2019,

465 Image_5.tif. 2019,

464 Image_6.tif. 2019,

463 Image_7.tif. 2019,

462 Image_8.tif. 2019,

461 Image_9.tif. 2019,

460 Table_1.xlsx. 2019,

459 Data_Sheet_1.DOCX. 2020,

458 Table_1.XLSX. 2020,

457 Table_2.XLSX. 2020,

456 Table_3.XLSX. 2020,

455 Table_4.XLSX. 2020,

454 Table_5.XLSX. 2020,

453 Table_6.XLSX. 2020,

452 Data_Sheet_1.docx. 2020,

451 Table_1.XLSX. 2020,

450 Data_Sheet_1.PDF. 2020,

449 Table_1.XLSX. 2020,

448 Table_2.XLSX. 2020,

447 Table_3.XLSX. 2020,

446 Table_4.XLSX. 2020,

445 Data_Sheet_1.PDF. 2019,

444 Table_1.xlsx. 2019,

443 Data_Sheet_1.pdf. 2019,

442 Data_Sheet_10.xlsx. 2019,

441 Data_Sheet_11.pdf. 2019,

440 Data_Sheet_12.xlsx. 2019,

439 Data_Sheet_13.pdf. 2019,

438 Data_Sheet_14.XLSX. 2019,

437 Data_Sheet_2.pdf. 2019,

436 Data_Sheet_3.pdf. 2019,

435 Data_Sheet_4.pdf. 2019,

434 Data_Sheet_5.pdf. 2019,

433 Data_Sheet_6.xlsx. 2019,

432 Data_Sheet_7.pdf. **2019,**

431 Data_Sheet_8.xlsx. **2019,**

430 Data_Sheet_9.xlsx. **2019,**

429 Image_1.pdf. **2019,**

428 Data_Sheet_1.PDF. **2018,**

427 Data_Sheet_2.pdf. **2018,**

426 Data_Sheet_3.PDF. **2018,**

425 Presentation_1.pptx. **2018,**

424 Table_1.DOCX. **2018,**

423 Table_2.XLSX. **2018,**

422 Table_3.xlsx. **2018,**

421 DataSheet_1.docx. **2020,**

420 DataSheet_2.zip. **2020,**

419 DataSheet_3.zip. **2020,**

418 DataSheet_4.zip. **2020,**

417 Table_1.xlsx. **2020,**

416 Table_2.xlsx. **2020,**

415 Table_3.xlsx. **2020,**

414 Table_4.xlsx. **2020**,

413 Data_Sheet_1.pdf. **2020**,

412 Data_Sheet_1.pdf. **2019**,

411 Table_1.xlsx. **2019**,

410 Table_2.xls. **2019**,

409 Table_3.docx. **2019**,

408 Image_1.JPEG. **2020**,

407 Image_2.JPEG. **2020**,

406 Table_1.XLSX. **2020**,

405 Data_Sheet_1.pdf. **2020**,

404 Data_Sheet_1.pdf. **2019**,

403 Table_1.XLSX. **2019**,

402 Data_Sheet_1.docx. **2020**,

401 Table_1.docx. **2020**,

400 Image_1.TIF. **2020**,

399 Image_2.TIF. **2020**,

398 Image_3.TIF. **2020**,

397 Image_4.TIF. **2020**,

396 Table_1.XLSX. 2020,

395 Data_Sheet_1.ZIP. 2019,

394 Data_Sheet_2.ZIP. 2019,

393 Data_Sheet_3.ZIP. 2019,

392 Data_Sheet_4.ZIP. 2019,

391 Image_1.TIF. 2019,

390 Image_2.TIF. 2019,

389 Table_1.XLSX. 2019,

388 Table_2.XLSX. 2019,

387 Table_3.XLSX. 2019,

386 Table_4.XLSX. 2019,

385 Table_5.XLSX. 2019,

384 Table_6.XLSX. 2019,

383 Table_7.XLSX. 2019,

382 Table_8.XLSX. 2019,

381 Table_9.XLSX. 2019,

380 Nanoprobes for Visualization of Cancer Pathology in Vivo?. 2022, 80, 805

1

379 Clinical whole-genome sequencing in cancer diagnosis.. 2022,

0

- 378 Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.. **2022**, 2022, 8270305 1
- 377 Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.. **2022**, 0
- 376 Insights into immune escape during tumor evolution and response to immunotherapy using a rat model of breast cancer.. **2022**, 1
- 375 Somatic mutation profiling in head and neck paragangliomas.. **2022**, 0
- 374 CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER.. **2019**, 58, 76-81
- 373 Perioperative systemic immunophenotype following irreversible electroporation (IRE) predicts recurrence.. **2022**, 12, 165-175
- 372 Cisplatin plus anti-PD-1 antibody enhanced treatment efficacy in advanced esophageal squamous cell carcinoma.. **2022**, 12, 451-468
- 371 Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing. 25,
- 370 Microfluidic harvesting of breast cancer tumor spheroid-derived extracellular vesicles from immobilized microgels for single-vesicle analysis.. **2022**, 0
- 369 Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.. **2022**, 183, 225-254 0
- 368 PersonaDrive: A Method for the Identification and Prioritization of Personalized Cancer Drivers.. **2022**, 0
- 367 Transcription Factor-Centric Approach to Identify Non-recurring Putative Regulatory Drivers in Cancer. **2022**, 36-51
- 366 Population-level Outcomes of Early Thyroid Cancers: A Need to Revisit Current Practice.. **2022**, 13,
- 365 Exploring Tumor Immune Microenvironment and Its Associations With Molecular Characteristics in Melanoma.. **2022**, 12, 821578 0
- 364 Dissecting the Genetic and Non-Genetic Heterogeneity of Acute Myeloid Leukemia Using Next-Generation Sequencing and In Vivo Models.. **2022**, 14, 0
- 363 Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.. **2022**, 11, 0
- 362 Genome interpretation using in silico predictors of variant impact.. **2022**, 1 0
- 361 Prognostic Significance of the Loss of Heterozygosity of in Early-Stage Lung Adenocarcinoma.. **2022**, 12, 873532 0

360	Paradoxical Behavior of Oncogenes Undermines the Somatic Mutation Theory. 2022 , 12, 662	1
359	Genetic and Clinical Characteristics of Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival.. 2022 , 14,	0
358	Regression-based heterogeneity analysis to identify overlapping subgroup structure in high-dimensional data.. 2022 ,	
357	OMEN: Network-based Driver Gene Identification using Mutual Exclusivity.. 2022 ,	
356	Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology. 2022 , 13,	
355	N-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma.. 2022 , 21, 111	1
354	Revival and Recharacterization of a Preclinical Model of Hormone-Dependent Breast Cancer to Study Immunotherapy.. 2022 , OF1-OF2	
353	Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms.. 2022 , 1-11	1
352	Comprehensive molecular characterization of hypertension-related genes in cancer.. 2022 , 8, 10	
351	Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy. 2022 , 13,	0
350	Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.. 2022 , 13, 2436	1
349	Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma.. 2022 ,	1
348	TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5.. 2022 , 20, 191	0
347	The translational challenges of precision oncology.. 2022 ,	3
346	Multi-Omic Data Improve Prediction of Personalized Tumor Suppressors and Oncogenes. 2022 , 13,	0
345	3'untranslated regions of tumor suppressor genes evolved specific features to favor cancer resistance.. 2022 ,	
344	Deciphering the tumor cell-infiltrating landscapes reveal microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.. 2022 ,	0
343	Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.. 2022 , 100969	0

- 342 Charted Territory: Evidence from Mapping the Cancer Genome and R&D Decisions in the Pharmaceutical Industry.
- 341 The molecular characteristics of gastric cancer patients living in Qinghai-Tibetan Plateau.. **2022**, 22, 244 0
- 340 Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers.. **2022**, 13, 2485 4
- 339 Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.. **2022**, 42, 1-14 1
- 338 PWWP2B promotes DNA end resection and homologous recombination.. **2022**, e53492 0
- 337 Individualized discovery of rare cancer drivers in global network context.. **2022**, 11, 1-11 0
- 336 A novel machine learning model for identifying patient-specific cancer driver genes. **2022**, 1-1 0
- 335 Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy. **2022**, 1-1 0
- 334 Stereotactic Body Radiation in Breast Cancer [Definitive, Oligometastatic, and Beyond]. **2022**, 1-1 0
- 333 Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. **2022**, 23, 5731 1
- 332 PhiDsc: Protein functional mutation Identification by 3D Structure Comparison. **2022**, 1-1 0
- 331 Zygotic genome activation by the totipotency pioneer factor Nr5a2. **2022**, 1-1 0
- 330 Alterations in transcriptional networks in cancer: the role of noncoding somatic driver mutations. **2022**, 75, 101919 1
- 329 New Treatment Options for Patients With Bladder Cancer. **2022**, 20, 570-572 1
- 328 Network Control Models With Personalized Genomics Data for Understanding Tumor Heterogeneity in Cancer. 12, 1-12 0
- 327 Identification of lung cancer drivers by comparison of the observed and the expected numbers of missense and nonsense mutations in individual human genes. **2022**, 13, 756-767 1
- 326 The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. 13, 1-13 4
- 325 Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure. **2022**, 1-1 0

324	Topography of mutational signatures in human cancer.	0
323	Examining clustered somatic mutations with SigProfilerClusters.	1
322	Stepwise evolutionary genomics of early-stage lung adenocarcinoma manifesting as pure, heterogeneous and part-solid ground-glass nodules.	0
321	Zooming on T cells in cancer.	0
320	Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm.	
319	Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. 2022,	1
318	The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers. 2022, 13,	3
317	APOBEC mutagenesis is low in most types of non-B DNA structures. 2022, 104535	0
316	Integrated proteogenomic characterization of urothelial carcinoma of the bladder. 2022, 15,	0
315	Clonal dynamics of haematopoiesis across the human lifespan. <i>Nature,</i>	50.4 7
314	Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample. 2022, 13,	
313	Using CRISPR-Cas9 to Dissect Cancer Mutations in Cell Lines. 2022, 235-260	
312	A Stress Response that Allows Highly Mutated Eukaryotic Cells to Survive and Proliferate.	
311	Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell LinesAn Isobolographic Analysis. 2022, 23, 6752	0
310	Gene Mutational Clusters in the Tumors of Colorectal Cancer Patients With a Family History of Cancer. 12,	1
309	Identification of cancer-keeping genes as therapeutic targets by finding network control hubs.	
308	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. 2022, 13,	3
307	APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?. 2022, 9,	0

306	Somatic point mutations are enriched in non-coding RNAs with possible regulatory function in breast cancer. 2022 , 5,	0
305	Evolutionary action of mutations reveals antimicrobial resistance genes in Escherichia coli. 2022 , 13,	2
304	Human Papillomavirus Integration Strictly Correlates with Global Genome Instability in Head and Neck Cancer. OF1-OF9	0
303	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. 2022 ,	2
302	Identifying the Potential Roles of PBX4 in Human Cancers Based on Integrative Analysis. 2022 , 12, 822	
301	A single-cell atlas of tumor-infiltrating immune cells in pancreatic ductal adenocarcinoma. 2022 , 100258	
300	Cancers adapt to their mutational load by buffering protein misfolding stress.	
299	Deep Sequencing of Early T Stage Colorectal Cancers Reveals Disruption of Homologous Recombination Repair in Microsatellite Stable Tumours with High Mutational Burdens. 2022 , 14, 2933	
298	Genome-wide mapping of somatic mutation rates uncovers drivers of cancer.	1
297	Heterogeneity in Melanoma. 2022 , 14, 3030	0
296	Gene Mutations Related to Glucocorticoid Resistance in Pediatric Acute Lymphoblastic Leukemia. 10,	
295	Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. 2022 , 109, 102429	2
294	Genomic Characteristics, Metabolic Signature and Immune Microenvironment of &i>Clonorchis Sinensis&/i>-Related Intrahepatic Cholangiocarcinoma.	
293	Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. 12,	
292	Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer. 2022 , 24,	0
291	Structural variations in cancer and the 3D genome.	0
290	The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. 2022 , 13,	0
289	LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma. 2022 , 101, e29763	

288	Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. 2022,	1
287	A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma.	2
286	Genomic and transcriptomic analysis of Korean colorectal cancer patients. 2022, 44, 967-979	
285	A bioinformatics roadmap for therapy selection in cancer genomics.	2
284	Spatiotemporal genomic analysis reveals distinct molecular features in recurrent stage I non-small cell lung cancers. 2022, 40, 111047	1
283	AACR Project GENIE: 100,000 cases and beyond.	2
282	The role of toll-like receptors (TLRs) in pan-cancer. 2022, 54, 1918-1937	
281	Structural variants shape driver combinations and outcomes in pediatric high-grade glioma.	1
280	Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure. 2022, 13,	0
279	An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. 12,	0
278	DriverRWH: discovering cancer driver genes by random walk on a gene mutation hypergraph. 2022, 23,	0
277	Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta-analysis.	
276	SYSMut: decoding the functional significance of rare somatic mutations in cancer. 2022, 23,	
275	Prognostic value and potential biological functions of ferroptosis-related gene signature in bladder cancer. 2022, 24,	0
274	Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma. 2022, 2022, 1-20	0
273	The Role of Tetraspanins in Pan-Cancer. 2022, 104777	2
272	Characterization of the Immune Infiltration Landscape and Identification of Prognostic Biomarkers for Esophageal Cancer.	2
271	Activating mTOR mutations are detrimental in nutrient-poor conditions..	1

270	Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms.	0
269	Genetics of testicular cancer: a review. Publish Ahead of Print,	0
268	Activation of the integrated stress response is a vulnerability for multidrug-resistant FBXW7-deficient cells.	1
267	Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites. 13,	1
266	A quantification method of somatic mutations in normal tissues and their accumulation in pediatric patients with chemotherapy. 2022 , 119,	0
265	A comprehensive multi-omics analysis reveals molecular features associated with cancer via RNA cross-talks in the Notch signaling pathway. 2022 ,	
264	Systematic integration of protein affecting mutations, gene fusions, and copy number alterations into a comprehensive somatic mutational profile.	
263	Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. 2022 , 14, 3674	0
262	The shaping of cancer genomes with the regional impact of mutation processes. 2022 , 54, 1049-1060	0
261	Discovering the drivers of clonal hematopoiesis. 2022 , 13,	1
260	Indigenous Causes of Human Papilloma Virus Negative Non-habit-associated Oral Squamous Cell Carcinoma: Perspectives and Prospects. 2022 , 13, 540-542	
259	SECEDO: SNV-based subclone detection using ultra-low coverage single-cell DNA sequencing.	
258	Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma. 2022 , 14,	1
257	iCOMIC: a graphical interface-driven bioinformatics pipeline for analyzing cancer omics data. 2022 , 4,	0
256	Crosstalk of three novel types of programmed cell death defines distinct microenvironment characterization and pharmacogenomic landscape in breast cancer. 13,	
255	Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma. 12,	0
254	Assessing the Performance of Methods for Cell Clustering from Single-cell DNA Sequencing Data.	
253	Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. 2022 , 28, 1646-1655	2

- 252 Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. **2022**, 28, 1619-1629 3
- 251 Comprehensive analyses of partially methylated domains and differentially methylated regions in esophageal cancer reveal both cell-type- and cancer-specific epigenetic regulation.
- 250 dN/dS-H, a New Test to Distinguish Different Selection Modes in Protein Evolution and Cancer Evolution.
- 249 Novel Driver Strength Index highlights important cancer genes in TCGA PanCanAtlas patients. 10, e13860
- 248 Clonality in immune aplastic anemia: mechanisms of immune escape or malignant transformation. **2022**, 0
- 247 Optimal Cancer Evasion in a Dynamic Immune Microenvironment. 0
- 246 Homeostasis limits keratinocyte evolution. **2022**, 119, 0
- 245 The multifaceted mechanisms of malignant glioblastoma progression and clinical implications. 0
- 244 Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. **2022**, 13, 1
- 243 Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. **2022**, 11, 2505 1
- 242 Pan-cancer integrative histology-genomic analysis via multimodal deep learning. **2022**, 40, 865-878.e6 3
- 241 Germline cancer gene expression quantitative trait loci influence local and global tumor mutations.
- 240 What is the status of immunotherapy in thyroid neoplasms?. 13, 0
- 239 Chromatin accessibility of primary human cancers ties regional mutational processes and signatures with tissues of origin. **2022**, 18, e1010393 0
- 238 Triple negative breast cancer: Pitfalls and progress. **2022**, 8, 8
- 237 RB1 loss triggers dependence on ESRRG in retinoblastoma. **2022**, 8, 0
- 236 Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. 0
- 235 Treatment Resistance to Melanoma Therapeutics on a Single Cell Level.

- 234 Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature. **2022**, 12, 1302 ○
- 233 Germline VWF/MPRIIP and somatoplasm FGA variants synergically confer susceptibility to non-traumatic osteonecrosis of the femoral head. ○
- 232 Mapping the landscape of genetic dependencies in chordoma. ○
- 231 Identification of lactate metabolism-related subtypes and development of a lactate-related prognostic indicator of lung adenocarcinoma. 13, ○
- 230 Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents. 10, ○
- 229 Structural aspects of chemical modifications in the MHC-restricted immunopeptidome; Implications for immune recognition. 10, 1
- 228 Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer. ○
- 227 Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. **2022**, 14, ○
- 226 Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms tumor. ○
- 225 DEGBOE: Discrete time Evolution modeling of Gene mutation through Bayesian inference using qualitative Observation of mutation Events. **2022**, 134, 104197 ○
- 224 Research progress of neoantigens in gynecologic cancers. **2022**, 112, 109236 ○
- 223 A nonlinear model and an algorithm for identifying cancer driver pathways. **2022**, 129, 109578 ○
- 222 A model and cooperative co-evolution algorithm for identifying driver pathways based on the integrated data and PPI network. **2023**, 212, 118753 ○
- 221 Multi-omics Data Integration Model Based on UMAP Embedding and Convolutional Neural Network. **2022**, 21, 117693512211242 1
- 220 Systematic Integration of Protein Affecting Mutations, Gene Fusions, and Copy Number Alterations Into a Comprehensive Somatic Mutational Profile. ○
- 219 SNPs Ability to Influence Disease Risk: Breaking the Silence on Synonymous Mutations in Cancer. **2022**, 77-96 ○
- 218 High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities. ○
- 217 Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape. 13, ○

216	Ferroptosis-Related Long Noncoding RNAs Have Excellent Predictive Ability for Multiomic Characteristics of Bladder Cancer. 2022 , 2022, 1-30	0
215	Prediction of cancer driver genes through integrated analysis of differentially expressed genes at the individual level.	0
214	Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers. 2022 , 12, 692-700	0
213	SCsnvcna: Integrating SNVs and CNAs on a phylogenetic tree from single-cell DNA sequencing data.	0
212	Drug Targeting of Chromosomal Translocations in Fusion-Positive Sarcoma.	0
211	Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. 2022 , 14, 4201	0
210	Biomarkers in Urological Cancers. 2022 , 37-76	0
209	Diffuse Large B-Cell Lymphomas: From Morphology to Genomic Profiling.	0
208	Failure of human rhombic lip differentiation underlies medulloblastoma formation. 2022 , 609, 1021-1028	2
207	Signatures 1 and 17 show increased propensity to create mutational hotspots in the human genome.	1
206	An Immune-Related Clinical-Gene-Risk-Score (CGRS) prognosis Model for Bladder Cancer.	0
205	Divergence of mutational signatures in association with breast cancer subtype.	1
204	Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation.	0
203	A Novel Cuproptosis-Related Gene Model Predicts Outcomes and Treatment Responses in Pancreatic Adenocarcinoma.	0
202	Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia.	5
201	Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. 2022 , 132,	2
200	Molecular subtyping of SCLC based on mutational signatures with different genomic features and therapeutic strategies.	0
199	Identification and validation of an inflammation-related lncRNAs signature for improving outcomes of patients in colorectal cancer. 13,	0

198	DEText: An SNV detection enhancement for low read depth by integrating mutational signatures into TextCNN. 13,	0
197	Integrated cohort of esophageal squamous cell cancer reveals genomic features underlying clinical characteristics. 2022, 13,	0
196	Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.	0
195	MODIG: integrating multi-omics and multi-dimensional gene network for cancer driver gene identification based on graph attention network model.	0
194	The Role of Immunotherapy in Pancreatic Cancer. 2022, 29, 6864-6892	1
193	Sources of Cancer Neoantigens beyond Single-Nucleotide Variants. 2022, 23, 10131	1
192	STING Agonists in Head and Neck Squamous Cell Carcinoma. 2022, 28, 401-406	1
191	Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. 2022, 14, 2076	2
190	Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry. 2022, 2, 1005-1016	1
189	Effects of replication domains on genome-wide UV-induced DNA damage and repair. 2022, 18, e1010426	0
188	Generating a genetic road map of childhood acute lymphoblastic leukemia. 2022, 54, 1267-1268	0
187	The genomic landscape of pediatric acute lymphoblastic leukemia. 2022, 54, 1376-1389	7
186	An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. 2022, 6,	1
185	Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment.	2
184	A Genomically and Clinically Annotated Patient-Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer.	0
183	Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPAR γ by inverse agonists. 2022, 102539	0
182	Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer.	0
181	Computational interpretation of human genetic variation. 2022, 141, 1545-1548	0

- 180 Integrative genomic analysis facilitates precision strategies for glioblastoma treatment. **2022**, 105276 ○
- 179 Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. **2022**, ○
- 178 Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective. **2022**, 215945 ○
- 177 The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. 12, ○
- 176 Somatic mutation variant analysis in rural, resectable non-small cell lung carcinoma patients. **2022**, 268-269, 75-82 ○
- 175 Epistasis and evolutionary dependencies in human cancers. **2022**, 77, 101989 ○
- 174 Molecular map of chronic lymphocytic leukemia and its impact on outcome. 3
- 173 Personalized Cancer Vaccines Targeting Neoantigens. **2022**, 1-21 ○
- 172 Cancer Immunotherapy Clinical Trials. **2022**, 1-24 ○
- 171 Personalized Treatment in Immunotherapy for Gynecologic Cancer. **2022**, 77-85 ○
- 170 Prinzipien der zellulären Tumorgenese und -progression. **2022**, 835-849 ○
- 169 Advances in the Application of Nanomaterials to the Treatment of Melanoma. **2022**, 14, 2090 ○
- 168 Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset. ○
- 167 Cancer Genomics and Evolution. 1-30 ○
- 166 Discovering cryptic splice mutations in cancers via a deep neural network framework. ○
- 165 Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy. **2022**, 5, e202201551 ○
- 164 COOBoostR: an extreme gradient boosting-based tool for robust tissue or cell-of-origin prediction of tumors. ○
- 163 Oncolytic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. **2022**, 23, 12647 ○

162	The mutational landscape of cancer's vulnerability to ionizing radiation.	1
161	Advanced Bladder Cancer: Changing the Treatment Landscape. 2022 , 12, 1745	1
160	Network Embedding Framework for Driver Gene Discovery by Combining Functional and Structural Information.	0
159	Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors.	0
158	Repulsion and attraction in searching: A hybrid algorithm based on gravitational kernel and vital few for cancer driver gene prediction. 2022 , 106236	1
157	Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism.	1
156	Ultraviolet Radiation Carcinogenesis. 1-6	0
155	How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care. 2022 , 58, 1386	0
154	Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile. 2022 , 10, 2732	0
153	A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma. 2022 , 22,	0
152	Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?. 13,	1
151	The targets of aspirin in bladder cancer: bioinformatics analysis. 2022 , 22,	0
150	Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. 2022 , 156, 113906	0
149	Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer. 2022 ,	0
148	Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles. 2022 ,	0
147	Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers. 2022 , 13,	0
146	Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer. 2022 , 13,	1
145	The bromodomain protein TRIM28 controls the balance between growth and invasiveness in melanoma.	0

144	Molecular Pathogenesis of Myeloproliferative Neoplasms.	2
143	CoMutDB: the landscape of somatic mutation co-occurrence in cancers.	0
142	A hitchhiker's guide to cell-free DNA biology. 2022 , 4, ii6-ii14	0
141	Expression pattern of secretory-cell-related transcriptional signatures in colon adenocarcinomas defines tumor microenvironment characteristics and correlates with clinical outcomes.	0
140	Inferring parameters of cancer evolution in chronic lymphocytic leukemia. 2022 , 18, e1010677	0
139	Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes.	0
138	Very large hidden genetic diversity in one single tumor [Evidence for tumors-in-tumor.	0
137	Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma.	0
136	Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. 2022 , 19,	0
135	Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. 2022 , 24,	0
134	Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma. 2022 , 11,	0
133	Epithelial and stromal co-evolution and complicity in pancreatic cancer.	0
132	Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.	0
131	Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target.	0
130	An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. 13,	1
129	Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. 2022 , 13,	1
128	Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. 2022 , 2, 671-691	0
127	Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer. 2022 , 14, 5817	0

126	Intratumor heterogeneity is associated with less CD8+ T cell infiltration and worse survival in patients with small cell lung cancer.	0
125	Regional mutational signature activities in cancer genomes. 2022 , 18, e1010733	0
124	Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy. 2022 , 29,	0
123	Integrated analysis of racial disparities in genomic architecture identifies a trans-ancestry prognostic subtype in bladder cancer.	0
122	Proteogenomic characterization of MiT family translocation renal cell carcinoma. 2022 , 13,	0
121	Article Review: Biochemical Aspect of Survivin Hormone. 2022 , 1, 1-15	0
120	DGMP: Identifying Cancer Driver Genes by Jointing DGCN and MLP from Multi-omics Genomic Data. 2022 ,	0
119	Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens. 2022 , 13,	0
118	Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes. 2023 , 15, 18	0
117	Importance of pharmacologic considerations in the development of targeted anticancer agents for children. Publish Ahead of Print,	0
116	Spatial biology of cancer evolution.	4
115	Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response. 2022 , 6,	0
114	Zygotic genome activation by the totipotency pioneer factor Nr5a2. 2022 , 378, 1305-1315	0
113	The Transition from Cancer Omics to Epi-omics through Next- and Third-Generation Sequencing. 2022 , 12, 2010	0
112	Genetic variants in African-American and Hispanic patients with breast cancer. 2022 , 25,	0
111	Cancer Genomics. 2022 , 53, 723-731	1
110	Complex patterns of genomic heterogeneity identified in 42 tumor samples and ctDNA of a pulmonary atypical carcinoid patient.	0
109	Immunotherapies targeting neoantigens are effective in PD -1 blockade-resistant tumors.	0

108	Immunotherapy for Esophageal Cancer. 2023 , 1-22	0
107	Whole exome sequencing in Chinese mucinous pulmonary adenocarcinoma uncovers specific genetic variations different from lung adenocarcinoma. 2022 , 12,	0
106	Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer. 2022 , 12,	0
105	Identification of a Novel Myc-Regulated Gene Signature for Patients with Kidney Renal Clear Cell Carcinoma. 2022 , 2022, 1-21	0
104	A Network-Based Voting Method for Identification and Prioritization of Personalized Cancer Driver Genes. 2022 , 148-158	0
103	Transcriptomics of mussel transmissible cancer MtrBTN2 reveals accumulation of multiple cancerous traits and oncogenic pathways shared among bilaterians.	0
102	Mechanisms of Resistance to Immunotherapies in Cancer. 2023 , 1-30	0
101	Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance. 2023 , 24, 1601	0
100	A Hypoxia Molecular Signature-Based Prognostic Model for Endometrial Cancer Patients. 2023 , 24, 1675	0
99	Characterization of Pancreatic Cancer with Ultra-low Tumor Mutational Burden.	0
98	Strahlentherapie und Immuntherapie. 2023 , 1-20	0
97	Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses. 2023 , 18, e0280364	0
96	Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.	0
95	A phase I trial of VEGF-A inhibition combined with PD-L1 blockade for recurrent glioblastoma.	0
94	Genomic profiling of metastatic basal cell carcinoma reveals candidate drivers of disease and therapeutic targets. 2023 , 100099	0
93	Cordycepin and kinase inhibition in cancer. 2023 , 28, 103481	0
92	Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.	1
91	IMRDriver: coding and non-coding cancer driver genes identification based on network propagation. 2022 ,	0

- 90 Advancements in Cancer Immunotherapies. **2023**, 11, 59 ○
- 89 Whole-genome characterization of myoepithelial carcinomas of the soft tissue. **2022**, 8, a006227 ○
- 88 A network-based method for identifying cancer driver genes based on node control centrality. 153537022211392
- 87 COOBoostR: An Extreme Gradient Boosting-Based Tool for Robust Tissue or Cell-of-Origin Prediction of Tumors. **2023**, 13, 71 ○
- 86 Identification of personalized driver genes for individuals using graph convolution network. **2022**, ○
- 85 Metastasis. **2021**, 597-631 ○
- 84 The ETS transcription factor ETV6 constrains the transcriptional activity of EWSR1 to promote Ewing sarcoma. ○
- 83 Non-Association of Driver Alterations in PTEN with Differential Gene Expression and Gene Methylation in IDH1 Wildtype Glioblastomas. **2023**, 13, 186 ○
- 82 SWEET: a single-sample network inference method for deciphering individual features in disease. ○
- 81 An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis. **2023**, 15, 736 ○
- 80 Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. **2023**, 22, 153303382211505 ○
- 79 Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer. **2023**, 42, ○
- 78 GASN: gamma distribution test for driver genes identification based on similarity networks. 1-19 ○
- 77 Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. **2023**, ○
- 76 Recent Progress in Immunotherapy for Gastric Cancer. **2023**, 23, 207 ○
- 75 Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. ○
- 74 Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment. **2023**, 25, ○
- 73 Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. Publish Ahead of Print, ○

- 72 Image-Based Deep Neural Network for Individualizing Radiotherapy Dose Is Transportable Across Health Systems. **2023**, ○
- 71 Immunotherapy: Targeting Cancer Cells. **2023**, 179-217 ○
- 70 Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma. **2023**, 14, ○
- 69 Germline VWF/MPRIIP and somatoplasm FGA variants synergically confer susceptibility to non-traumatic osteonecrosis of the femoral head. **2023**, 13, ○
- 68 A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers. **2023**, 116, 109821 ○
- 67 Personalized medicine from translational research to clinical practice. ○
- 66 In situ analysis of immune checkpoint molecule on bladder cancer cell based on cellular interface supported cascade signal amplification mediated by CRISPR/Cas13a system. **2023**, 133784 ○
- 65 Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. ○
- 64 Identifying cancer driver genes using a two-stage random walk with restart on a gene interaction network. **2023**, 158, 106810 ○
- 63 Constructing metabolism-protein interaction relationship to identify glioma prognosis using deep learning. **2023**, 158, 106875 ○
- 62 Landscape of chromatin remodeling gene alterations in endometrial carcinoma. **2023**, 172, 54-64 ○
- 61 Noninvasive genomic profiling of somatic mutations in oral cavity cancers. **2023**, 140, 106372 ○
- 60 Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. **2023**, 26, 169-180 ○
- 59 Immunotherapy in Small Cell Lung Cancer. 43-53 ○
- 58 Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. **2022**, 1-34 ○
- 57 Immune-Activated B Cells Are Dominant in Prostate Cancer. **2023**, 15, 920 1
- 56 WMDS.net: a network control framework for identifying key players in transcriptome programs. **2023**, 39, ○
- 55 Targeting Staphylococcus aureus dominated skin dysbiosis in actinic keratosis to prevent the onset of cutaneous squamous cell carcinoma: Outlook for future therapies?. 13, ○

54	MUC17 mutations are associated with poor prognosis in both adult low-grade glioma and glioblastoma patients.	0
53	Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy. 13,	0
52	Integrating multi-type aberrations from DNA and RNA through dynamic mapping gene space for subtype-specific breast cancer driver discovery. 11, e14843	0
51	Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance. 2023 , 14,	1
50	Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. 2023 , 178, 96-102	0
49	Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.	1
48	The Landscape of Immunotherapy for Retroperitoneal Sarcoma. 2023 , 30, 2144-2158	0
47	Insilico Identification of MHC displayed Tumor Associated Peptides in Ovarian Cancer for Multi-Epitope Vaccine Construct.	0
46	An Integrative Analysis of Nasopharyngeal Carcinoma Genomes Unraveled Unique Processes Driving a Viral-Positive Cancer. 2023 , 15, 1243	0
45	A novel cuproptosis-related signature for predicting prognosis and immune response in gastric cancer.	0
44	Clinical Cancer Genomic Diagnostics and Modern Diagnostic Pathology. 1-13	0
43	Genomics-Driven Precision Medicine in Pediatric Solid Tumors. 2023 , 15, 1418	0
42	CRISPR-Cas9 Targeted Enrichment and Next-Generation Sequencing for Mutation Detection. 2023 ,	0
41	Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer. 2023 , 21,	0
40	Identification of Cancer Driver Genes by Integrating Multiomics Data with Graph Neural Networks. 2023 , 13, 339	0
39	LRT-CLUSTER: A New Clustering Algorithm Based on Likelihood Ratio Test to Identify Driving Genes.	0
38	Unified views on variant impact across many diseases. 2023 ,	0
37	Immunogenic cell death in cancer: concept and therapeutic implications. 2023 , 21,	0

- 36 Identification of a necroptosis-related gene signature as a novel prognostic biomarker of cholangiocarcinoma. 14,
- 35 Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. **2023**, 24, 4786
- 34 An oncospace for human cancers. **2023**, 45,
- 33 Improved detection of homologous recombination deficiency in Chinese patients with ovarian cancer: a novel non-exonic single-nucleotide polymorphism-based next-generation sequencing panel.
- 32 In vivo interrogation of regulatory genomes reveals extensive quasi-insufficiency in cancer evolution. **2023**, 3, 100276
- 31 Pan-cancer analysis reveals signal transducer and activator of transcription (STAT) gene family as biomarkers for prognostic prediction and therapeutic guidance. 14,
- 30 A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma. **2023**, 23,
- 29 RNA allelic frequencies of somatic mutations encode substantial functional information in cancers.
- 28 Nail Apparatus Melanoma: Current Management and Future Perspectives. **2023**, 12, 2203
- 27 Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer. **2023**, 4, 100974
- 26 An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer. **2023**, 13,
- 25 Characterization of pancreatic cancer with ultra-low tumor mutational burden. **2023**, 13,
- 24 Degree of Actinic Elastosis Is a Surrogate of Exposure to Chronic Ultraviolet Radiation and Correlates More Strongly with Cutaneous Squamous Cell Carcinoma than Basal Cell Carcinoma. **2023**, 13, 811
- 23 Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer.
- 22 Tumor grade-associated genomic mutations in Chinese patients with non-small cell lung cancer. 13,
- 21 HERVs and Cancer: A Comprehensive Review of the Relationship of Human Endogenous Retroviruses and Human Cancers. **2023**, 11, 936
- 20 Multi-omics Data Integration Model based on Isomap and Convolutional Neural Network. **2022**,
- 19 Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. **2023**, 23,

- 18 Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications. **2023**, 15, 1958 ○
- 17 Upregulation of ENKD1 disrupts cellular homeostasis to promote lymphoma development. ○
- 16 Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia. **2023**, 14, ○
- 15 Analysis of evolutionary dynamics and clonal architecture in prostate cancer. ○
- 14 Multiancestry genomic and transcriptomic analysis of gastric cancer. **2023**, 55, 581-594 ○
- 13 Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. **2023**, 15, 1959 ○
- 12 The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. **2023**, 24, 6710 ○
- 11 Mapping the landscape of genetic dependencies in chordoma. **2023**, 14, ○
- 10 Systematic integration of protein-affecting mutations, gene fusions, and copy number alterations into a comprehensive somatic mutational profile. **2023**, 100442 ○
- 9 The Swedish Childhood Tumor Biobank: Systematic collection and molecular characterization of all pediatric CNS and other solid tumors in Sweden. ○
- 8 Head and neck cancer treatment in the era of molecular medicine. **2023**, ○
- 7 Cancer driver mutations: predictions and reality. **2023**, ○
- 6 Integrative identification of non-coding regulatory regions driving metastatic prostate cancer. ○
- 5 Harnessing the Immunological Effects of Radiation to Improve Immunotherapies in Cancer. **2023**, 24, 7359 ○
- 4 Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data. 29, ○
- 3 Precision medicine: Overview and challenges to clinical implementation. **2023**, 513-529 ○
- 2 General aspects of cancer therapy. **2023**, 1-35 ○
- 1 Model selection and robust inference of mutational signatures using Negative Binomial non-negative matrix factorization. **2023**, 24, ○

